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1 Summary 
 
The aim of this study was to investigate the influence of diet-induced obesity, and the 
resulting changes in hormone metabolism, on amylin sensitivity and secretion. 
 
Our investigation resulted in the following findings and conclusions: 
 
First study 
Findings: After  eleven weeks on high fat-feeding, obese rats showed an attentuated anorectic 
response to exogenous amylin (5µg/kg). Further, high fat-feeding increased amylin and leptin 
baseline levels as well as total, visceral and subcutaneous body fat. 
Conclusion: Long-term high fat-feeding decreases sensitivity to peripheral amylin in obese 
rats. 
 
Second study 
Findings: Following chronic elevation of circulating amylin levels in non-obese rats, changes 
in amylin sensitivity to the acute anorectic effect of amylin were not observed. Exogenous 
amylin administration decreased food intake dose-dependently, regardless of circulating 
amylin levels, at least within the first hour after administration. 
Conclusion: Hyperamylinemia, without the influence of obesity, does not seem to reduce 
amylin’s anorectic effect. 
 
Third study 
Findings: After eight weeks on a high fat diet, diet-induced obese and diet resistant rats 
showed changes in meal induced amylin and insulin secretion pattern. In addition, baseline 
amylin, leptin and insulin levels increased with an increase in body weight. 
Conclusion: The differences in meal-induced amylin secretion seem to be influenced more by 
the composition of the diet than by the higher body weight of obese rats. On the other hand, 
mealtime insulin secretion is likely to be influenced more by actual body weight or fat mass.
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2 Introduction  
 
2.1 The Obesity Epidemic 
 
Obesity, which has reached epidemic proportions globally, is typically the result of an 
imbalance between energy intake and energy expenditure. Once associated with high-income 
countries, obesity is now also prevalent in low- and middle-income societies. The primary 
reasons for the global increase in overweight and obesity are the shift toward increased intake 
of an energy-dense diet that is high in fat and sugar, and a trend toward decreased physical 
activity. According to the World Health Organization (WHO), approximately 1.6 billion 
adults were overweight and at least 400 million adults were obese in 2005. Additionally, in 
2005 there were at least 20 million children under the age of five who were overweight. 
Worldwide there are more people who die from complications of obesity than from being 
underweight or malnourished. This  demonstrates the significance of this disease and its 
consequences (Flegal et al., 2007). 
 
Several health problems associated with obesity are frequently classified as symptoms of  
metabolic syndrome, including the development of insulin resistance, type 2 diabetes, fatty 
liver disease and cardiovascular disease. According to the WHO, more than 220 million 
people worldwide have diabetes, approximately 90% of which have type 2 diabetes; type  2 
diabetes is largely the result of excess body fat and physical inactivity (Katz et al., 2000). 
Some other consequences of obesity or type 2 diabetes include an increased risk of 
nephropathy, retinopathy, osteoarthritis, respiratory disease, sleep apnea and several types of 
cancer, as well as an increased general risk of mortality (Pi-Sunyer, 2002; Kesty et al., 2008). 
 
2.2 Current Therapeutic Approaches 
 
Prevention and early treatment of overweight and obesity can often be achieved by 
maintaining or restoring the balance between calories consumed and calories expended. In 
addition to a change in diet, physical activity may also be beneficial for weight control.  In 
most cases of overweight and obesity, however, diet and increased exercise do not produce 
sufficient weight loss. Bariatric surgical interventions, such as gastric bypass or gastric 
banding, are the most successful weight loss treatments (Dixon et al., 2005; le Roux et al., 
2007). However, such treatments are invasive and expensive, and are typically only 
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recommended to patients suffering from at least Class II obesity, with a BMI of 35 or greater 
(Rubino et al., 2004; Moo and Rubino, 2008). For overweight or obese patients with a BMI 
less than 35, pharmacological treatment is an alternate approach to weight loss management.  
While significant advances have been made in the development of potential drugs that can 
manage body weight as well as diabetes, subsequent progress is limited by not fully 
understanding the central and peripheral mechanisms that control energy homeostasis.  
Furthermore, we must also consider the potential consequences that the physical state of 
obesity may intrinsically have on the success of such therapies.         
 
It is known that numerous metabolic, neuronal and endocrine signals are involved in 
controlling energy homeostasis and therefore also influence the development of obesity.  
Long-term adiposity (tonic) signals that represent the energy store of the body, such as leptin 
and insulin, and short term peripheral satiation (phasic) signals that are produced in response 
to the current nutritive state, such as amylin, CCK and GLP-1 are a few examples discussed 
below (Kesty et al., 2008). 
 
2.3 Controls of Energy Homeostasis 
 
Body mass and composition are a reflection of three processes of energy homeostasis: energy 
intake, energy storage and energy expenditure. Energy homeostasis is achieved when energy 
intake equals energy output, and obesity, or excess energy storage, results when energy 
consumption exceeds energy expenditure. Metabolic, neuronal and endocrine signals are 
involved in controlling energy homeostasis and these also play a role in the development of 
obesity. 
  
Most humans eat the same approximate numbers of meals, at a similar time of the day, on a 
daily basis. A variety of factors control meal onset and meal size (Woods, 2005). Social 
influences, emotions, time of day, even the convenience or the cost of food can lead to 
variability in daily energy intake within and among individuals (Edholm, 1977). In addition to 
these non-biological factors, a network of biological processes tightly controls energy 
homeostasis. The hormones and peptides, from both the periphery and the central nervous 
system, that converge in the brain to control meal-to-meal food intake are typically classified 
as hunger, satiation, or satiety signals. Another class of hormones, called adiposity signals, are 
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secreted in proportion to body fat and are thought to control food intake and body weight in 
the long-term in order to maintain stable body weight.  
   
2.3.1 Peripheral signals 
 
2.3.1.1 Hunger signals 
 
Identified in 1999, ghrelin is the only known peripheral peptide that stimulates appetite (Cui 
et al., 2008; Perboni and Inui, 2009). Ghrelin is a gastrointestinal (GI) hormone secreted from 
the enteroendocrine cells of the stomach, the small intestine and the colon into the portal vein 
(Kojima et al., 1999). It was recently suggested that ghrelin may act as an inverse adiposity 
signal, because plasma concentrations are low in obese individuals, and a loss of body weight 
in overweight humans is accompanied by an increase in circulating ghrelin concentration 
(Tschop et al., 2001; Hansen et al., 2002). Primarily linked to food intake, ghrelin levels rise 
and fall throughout the day. High ghrelin levels are observed following fasting or in 
anticipation of a meal, and levels decline after energy intake (Drazen et al., 2006; Cui et al., 
2008). However, the relevance of ghrelin as a physiological signal to trigger meal onset is 
unknown. 
 
2.3.1.2 Satiation and Satiety signals 
 
Satiation signals are released following meal initiation to limit meal size. During food 
consumption, most satiation signals are secreted and then act by either stimulating vagal 
afferents that project to the hindbrain or by stimulating the hindbrain directly. From here, the 
signals are relayed to other brain areas, where they are integrated with adiposity signals, as 
well as with information encoding hedonic and social factors, to eventually terminate eating 
(Woods, 2009). 
  
Cholecystokinin (CCK), which is mainly produced in the duodenum and jejunum, and is 
rapidly released into the circulation in response to local nutrients, is considered the 
prototypical satiation signal (Gibbs et al., 1973; Grider, 1994). CCK acts on the vagal nerve, 
which projects to the nucleus of the solitary tract (NTS) in the hindbrain, and possibly also 
directly on the CNS by crossing the blood-brain barrier (MacLean, 1985; Edwards et al., 
1986). Administration of CCK to humans and animals inhibits food intake by reducing meal 
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size and duration (Lieverse et al., 1995; Gibbs et al., 1997). However, because of CCK’s short 
half-life (approximately 1-2 min), and because continuous infusion of CCK becomes 
ineffective in decreasing meal size within 24 hours (Crawley and Beinfeld, 1983), CCK alone 
does not appear to be therapeutically relevant for the treatment of human obesity (Wynne et 
al., 2005), unless, perhaps, when the number of meals is  strictly controled. 
Another well studied satiation signal is glucagon-like peptide-1 (GLP-1), which is released 
during the meal from the L-cells of the GI tract and peaks post-prandially in proportion to the 
amount of energy ingested. GLP-1 is also produced in some neurons in the NTS (Chaudhri et 
al., 2008). GLP-1 reduces food intake when administered either peripherally or centrally 
(Baggio et al., 2004; Abbott et al., 2005). It has been demonstrated that i.p. infusion of GLP-1 
selectively reduced the duration and the size of the ongoing meal, without affecting the 
intermeal interval and the size of  subsequent meals (Ruttimann et al., 2009). With a short 
half-life of approximately 2 minutes, GLP-1 produces only a transient reduction in food 
intake when administered peripherally (Baggio and Drucker, 2007).  However, GLP-1 
receptor agonists designed with half-lives up to 8 days show promising potential for treatment 
of obesity or type 2 diabetes (Baggio et al., 2008). 
 
Upon termination of a meal, a state of non-eating, or satiety, begins and continues until the 
next meal is initiated.  This state is regulated by satiety signals (Williams et al., 2009). 
In addition to CCK and GLP-1, gastrin releasing peptide (Stein and Woods, 1982), 
neuromedin B (Ladenheim et al., 1996), enterostatin (Shargill et al., 1991), somatostatin 
(Lotter et al., 1981), apolipoprotein A-IV (Fujimoto et al., 1993) and peptide YY (Batterham 
et al., 2002) are also peptides secreted from the GI tract that have been shown to reduce meal 
size and which may perhaps also induce satiety when administered systemically. However, 
the latter effect needs to be studied in more detail. 
 
2.3.1.3 Adiposity signals  
  
Adiposity signals are hormones that are secreted in proportion to body fat; increased 
circulating levels of adiposity signals are indicative of a larger amount of stored fat. The two 
best investigated and most prominent adiposity signals are leptin and insulin. In normal-
weight animals, a change in circulating adiposity signals signifies a change in body fat stores, 
and typically results in a behavioral response. For instance, an increase in basal leptin or 
insulin would indicate a gain in body weight, and the animal would respond by consuming 
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less food to restore a lower body weight. When administered to an overweight or obese 
animal or human, however, these individuals are relatively insensitive to the food intake- and 
weight-reducing effects of adiposity signals (Woods, 2009). Thus, while obesity is associated 
with hyperinsulinemia and hyperleptinemia, it also generates resistance to these signals, 
which challenges their theurapeutic usefulness. 
 
Adipocyte-derived adiposity signals 
 
Leptin is a cytokine that is expressed and secreted primarily by adipocytes. Leptin levels 
increase with weight gain, and fasting levels are directly proportional to adipose mass (Maffei 
et al., 1995). Because fat cell size is usually enlarged 2 to 4 times in obese individuals, obesity 
can result in a seven-fold increase in leptin secretion compared to that seen in lean individuals 
(Fried et al., 2000). 
  
The plasma protein adiponectin is secreted exclusively from adipose tissue (Hu et al., 1996). 
Adiponectin may be considered an inverse adiposity signal because unlike  leptin, there is 
typically a strong negative correlation between the plasma adiponectin concentration and fat 
mass (Hu et al., 1996). Hence, while obesity lowers adiponectin levels, weight reduction 
increases circulating adiponectin. Adiponectin has been shown to improve the whole-body 
insulin sensitivity in models of genetic and diet-induced obesity (Combs et al., 2001). It is 
thought to stimulate fatty acid oxidation and glucose uptake in skeletal muscle and adipose 
tissue, thereby attenuating body-weight gain without affecting food intake (Berg et al., 2001; 
Yamauchi et al., 2002; Wu et al., 2003).  
 
Pancreatic ß-cell-derived adiposity signals 
 
Insulin demonstrably fulfils the criteria of a long-term adiposity signal, namely that observed 
plasma levels are positively correlated with body fat (Bagdade et al., 1967). While leptin is 
disproportionately secreted from subcutaneous fat, the insulin secretion more closely reflects 
the amount of visceral fat mass, thereby acting as a negative feedback signal (Considine et al., 
1996).  As with leptin, weight gain reduces insulin sensitivity, thus elevated insulin secretion 
in both the basal state and in response to meals is required if normal glucose homeostasis is to 
be maintained (Clegg et al., 2005). It has been shown in rats that insulin is secreted in a high-
frequency pulsatile manner (Matveyenko et al., 2008), and that during fasting,  the liver is 
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exposed to insulin oscillations of ∼400-600 pmol/l (Matveyenko et al., 2008). Hepatic insulin 
clearance is directly related to the amplitude of insulin pulses in the portal vein. Because 
approximately 80% of insulin is cleared in the first pass through the liver, systemic insulin 
concentrations may underestimate changes in insulin secretion, especially pulsatile insulin 
secretion (Matveyenko et al., 2008).  
 
2.3.1.4 Amylin 
 
The second peptide produced and secreted by the pancreatic ß-cells is amylin, which is the 
focus of this dissertation. Amylin, also known as islet amyloid polypeptide (IAPP), is co-
secreted with insulin in response to nutrient consumption (Ludvik et al., 1997). Amylin shares 
the typical characteristics of satiating hormones, like CCK, and plays a role in the control of 
meal size. Thus, in response to nutrient ingestion, circulating amylin concentrations rise 
rapidly, i.e. within minutes after meal onset, and peak within 60 min and then remain elevated 
for up to 4 hours after  a typical meal (Koda et al., 1992). When administered exogenously 
(peripheral or central), amylin dose-dependently decreases food intake, causing a decrease in 
meal size though having no effect on the intermeal interval (Lutz et al., 1995; Rushing et al., 
2001). Furthermore, the decrease in meal size is not a result of an aversive or toxic effect of 
amylin (Lutz et al., 1995; Mack et al., 2007).  
 
In addition to functioning as a satiation signal, amylin also meets the main criteria to be 
considered an adiposity signal. Similar to leptin and insulin, the basal plasma level of amylin 
is directly proportional to body adiposity (Pieber et al., 1994), with elevated fasting amylin 
concentrations in obese individuals that increase further with weight gain (Kesty et al., 2008). 
It has been shown that chronic subcutaneous administration of low doses of amylin to ad 
libitum fed rats reduces food intake and body weight gain (Arnelo et al., 1996; Arnelo et al., 
1998), and also causes a reduction in fat depot size (Isaksson et al., 2005). Additionally, a 
chronic infusion of amylin antagonists increases body weight and body fat mass (Rushing et 
al., 2001). These observations are consistent with the concept that amylin acts as an adiposity 
signal to control energy homeostasis. 
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2.3.2 Central processing of peripheral signals that are involved in the control of eating 
 
The brain receives and integrates multiple forms of information from numerous organs that 
are involved in energy homeostasis. Information regarding energy stores and fluxes in critical 
organs, the ingestion of food, and the basal and current energy need by various tissues is 
processed by the brain to maintain homeostasis.  The primary brain nuclei regulating energy 
balance are located in the hindbrain and the hypothalamus.   
 
2.3.2.1 The hindbrain 
 
The hindbrain, specifically the area postrema (AP) and the nucleus of the solitary tract (NTS), 
plays an important role in the control of food intake and body weight. It is a major site of 
abdominal sensory input to the central nervous system, to which vagal and splanchnic 
afferents from the abdominal viscera project directly or indirectly (Hyde and Miselis, 1983). 
Furthermore, the AP is a circumventricular organ, and hence lacks a functional blood brain 
barrier; this allows signals in the blood to directly access the receptors in the AP (Lutz et al., 
1998). Receptors for several satiation and adiposity signals are localized in the AP and NTS, 
including amylin, CCK, GLP-1, insulin, and leptin (Woods and D'Alessio, 2008). Neuronal 
populations expressing these receptors then convey information to various other brain regions. 
The AP has efferent projections to the NTS, the dorsal motor nuclei of vagus and the lateral 
parabrachial nuclei, whereas the NTS has efferent projections to the hypothalamus and limbic 
structures (Ricardo and Koh, 1978). Hypothalamic nuclei also send reciprocal projections 
back to the AP and the NTS (van der Kooy et al., 1984). Due to the presence of such receptors 
and neuronal connections, the AP/NTS has been proposed to act as a central receiver and 
processor of metabolic and humoral signals (Hyde and Miselis, 1983). This notion is 
supported by the fact that lesions of the AP/NTS induce a syndrome of hyperphagia in rats, 
which consequently gain more weight (Hyde and Miselis, 1983). The increase in body weight 
suggests a loss of visceral sensory input to various receptors both in and downstream of the 
AP/NTS, thus impairing homeostatic control on several levels.  
 
2.3.2.2 The hypothalamus 
 
While the hindbrain, containing motor output circuits and the neuronal processing for the 
control of meal size, plays a critical role in food intake, regulation of motivated ingestive 
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behavior requires contribution of the hypothalamus, which is situated in the medial basal 
forebrain (Swanson, 2000). Over half a century ago, seminal lesion studies identified the 
ventromedial hypothalamic nucleus (VMN) as the “satiety center,” and the lateral 
hypothalamic area (LHA) as the “hunger center” (Hetherington and Ranson, 1940; Anand and 
Brobeck, 1951). Even though this view is far too simplified, these nuclei remain important in 
energy homeostasis control. However, in recent years, and notably following the discovery of 
leptin in 1994 (Zhang et al., 1994; Halaas et al., 1995), considerable focus has been placed on 
the arcuate nucleus (ARC) as the central hypothalamic control of food intake.    
 
The ARC, which is located in the ventral hypothalamus, along with the median eminentia  
(Rethelyi, 1984), has a relatively leaky blood-brain barrier and expresses several important 
receptors that bind peptides involved in the control of energy homeostasis. Because of this, 
the ARC is ideally situated to gauge the circulating levels of adiposity signals. Upon binding 
to the ARC, leptin and insulin interact with two neuronal populations that synthesize either 
proopiomelanocortin (POMC) or neuropeptide Y (NPY) and Agouti-related peptide (AgRP); 
both populations are involved in energy homeostasis. POMC is cleaved to produce the 
neurotransmitter α-melanocyte stimulating hormone (α-MSH), which reduces food intake by 
activating melanocortin 3 (MC3R) and melanocortin 4 (MC4R) receptors found on neurons in 
other hypothalamic regions and elsewhere in the brain (Schwartz et al., 2000; Cone, 2005). 
NPY, on the other hand, acts at Y receptors to stimulate food intake (Stanley et al., 2005). 
AgRP is an endogenous MC3R and MC4R antagonist and therefore also acts as an orexigenic 
agent, countering the activity of POMC neurons (Cone, 2005). These neuronal populations 
project namely to the paraventricular nucleus (PVN) and the LHA, to further modulate food 
intake and energy expenditure. Stimulation of the PVN typically leads to a catabolic action 
that reduces food intake and increases energy expenditure, whereas stimulation of the LHA 
results in an anabolic process that increases food intake and body weight gain (Woods and 
D'Alessio, 2008). 
 
The long-form of the leptin receptor (ObR-L) is present in high concentrations in the ARC 
(Schwartz et al., 1996; Elmquist et al., 1998), and it has been shown that leptin reduces food 
intake and controls energy expenditure by activating POMC neurons and inhibiting NPY 
neurons (Elias et al., 1999). Insulin receptors are also located in the ARC and, like leptin, 
insulin stimulates the hypothalamic melanocortin system to carry out its catabolic action 
(Benoit et al., 2002). Finally, the orexigenic effect of ghrelin is mediated by the activation of 
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ARC neurons that co-express NPY and AgRP, and the indirect inhibition of POMC-
containing neurons (Riediger et al., 2003). These, and other data suggest that ghrelin acts in a 
functionally antagonistic manner to leptin and insulin in the ARC (Traebert et al., 2002). 
 
2.3.2.3 Central processing of amylin 
 
Specific amylin binding sites have been identified in various discrete brain nucluei in the 
telencephalon, hypothalamus and hindbrain (Sexton et al., 1994). Functional amylin receptors 
are composed of a calcitonin receptor (CT-R) core and receptor-activity modifying proteins 
(Christopoulos et al., 1999), normally RAMP1 or RAMP3. RAMPs regulate transport of core 
receptors to the cell surface, and are involved in ligand specificity of the receptor. All 
necessary components for the amylin receptor are located in the AP, which is thought to be 
the primary central target of circulating amylin (Lutz et al., 1998; Ueda et al., 2001). 
 
Lesion and immunohistochemical studies further confirm the importance of the AP in 
mediating amylin’s actions. Immunohistochemical detection of c-Fos expression is a 
commonly-used technique for mapping neuronal activation in the brain (Curran and Morgan, 
1995). Both exogenously applied and feeding induced endogenous amylin induces c-Fos in 
the AP/NTS region, as well as in other brain areas such as the lateral parabrachial nucleus 
(LPBN) and the central nucleus of the amygdala (Riediger et al., 2004). Lesions of the 
AP/NTS, but not blockade of neural afferents projecting to the brain, abolish the anorectic 
effect of amylin (Lutz et al., 1998).  Lesions of the AP have also been shown to attenuate the 
c-Fos response in the NTS, LPBN, and CeA, demonstrating the key role that the AP plays in 
mediating amylin’s action (Rowland and Richmond, 1999; Riediger et al., 2004).  
 
2.4 Obesity and Modified Homeostatic Control 
 
2.4.1 Rodent models of obesity 
 
To study how the obese state alters homeostatic regulation, numerous rodent models of 
obesity have been developed over the past half-century.  Obesity in rats can result from 
several factors, including spontaneous mutations, targeted, genetic modification, and 
environment (e.g. access to a diet high in fat). Such animal models are very important for 
studies probing the environmental influences on obesity (e.g. epigenetics), the responses to 
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diets containing various levels of fat, carbohydrates, protein, or calories, and the identification 
and development of pharmaceuticals for obesity treatment. Today there are several well-
established animals models available that provided an enormous amount of information about 
obesity. Models for physiological and genetic basis of obesity included e.g. the leptin-
deficient ob/ob mouse, the Zucker fa/fa rat and the Otsuka Long Evans Tokushima Fatty 
(OLETF) rat, which is CCK-1 receptor-deficient. The diet-induced obesity (DIO) rat model 
(Levin et al., 1997), which was used in the studies described below, is frequently used in 
research because it mimics the more common form of obesity in humans that is not caused by 
a specific mono-genetic mutation. 
 
Zucker fa/fa rats 
 
The Zucker-fatty rat was observed following a spontaneous mutation; fa/fa homozygous 
animals suffer from genetic obesity, and progressively accumulate fat mass, which is 
predominately subcutaneous, over their lifespan (Argiles, 1989; Moran, 2008). The fa gene 
mutation prevents expression of the long isoform of the leptin receptor (Phillips et al, 1996). 
Hyperphagia is one of the main characteristics of the obese Zucker-fatty rat (Bray and York, 
1972), however, the fact that pair-feeding obese rats with lean rats reduces, but does not 
prevent, the development of obesity, suggests that hyperphagia is not the only factor causing 
increased fat storage but that decreased energy expenditure may also be involved (Pullar and 
Webster, 1974). The obese Zucker rats are characterized as having hyperinsulinemia, which 
results from both hypertrophy and hyperplasia of the pancreatic ß-cells (Zucker and 
Antoniades, 1972), and from reduced hepatic clearance of the hormone (Argiles, 1989). 
Zucker-fatty rats are also glucagon resistant. Despite having normal pancreatic glucagon 
levels, basal plasma glucagon and plasma glucagon concentrations in response to fasting are 
decreased (Eaton et al., 1976; Argiles, 1989).  Obese Zucker rats are one of the best known 
and most widely used animal model for genetic obestity. Furthermore the Zucker diabetic 
fatty (ZDF) male rat is a rodent model of diabetes type 2 (Tokuyama et al., 1995). 
 
OLETF rats 
 
Obesity is also observed in Otsuka Long Evans Tokushima Fatty (OLETF) rats, which lack a 
functional CCK-1 receptor. Insensitivity to CCK leads to hyperphagia that is a consequence 
of a significant increase in meal size (Bi and Moran, 2002; Moran, 2008). OLETF rats 
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consume about 30% more than control Long Evans Tokushima Otsuka (LETO) rats, and fat 
deposition is predominately intra-abdominal or visceral, which is different from some other 
rat models (Kawano et al., 1994; Bi et al., 2001). 
OLETF rats were also used as a model of  type 2 diabetes and are characterized by late onset 
of hyperglycemia, polyuria, polydipsia and mild obesity (Kawano et al., 1994; Moran, 2008). 
 
Diet-induced obesity (DIO) and resistance in Sprague-Dawley rats 
 
A third rodent model of obesity, which was utilized in experiments conducted for this 
dissertation, is the DIO rat. As observed and described extensively by Levin and colleagues, 
when outbred Sprague-Dawley (SD) rats are fed a diet relatively high in fat, sucrose and 
energy density, approximately one-half will develop DIO, while the other half remain diet 
resistant (DR; (Levin et al., 1997). DR rats gain body weight and fat mass at a rate similar to 
that observed in chow-fed control rats (Levin and Keesey, 1998). Despite the fact that high-fat 
diets are generally known to stimulate insulin resistance in rats, only the DIO animals 
developed glucose intolerance and relative insulin resistance on high-energy (HE) diets. In 
addition to investigating the effects of diet on outbred SD rats, DIO and DR rats have also 
been selectively bred, which allows for the study of multi-genetic and experimental factors 
that might predispose an individual to obesity, prior to consumption of a high-fat diet (Ricci 
and Levin, 2003).  
 
Rodent DIO is an appealing model because it shares several characteristics with common 
forms of human obesity. Namely, and unlike the obese Zucker or OLFTF rats, it is known that 
the bimodal pattern of body weight development in SD rats fed a HE diet is not due to a 
modification in a single gene (Levin et al., 1997). Like most cases of human obesity, the DIO 
model results from a combination of both inherited and environmental factors. Induction of 
complete DIO is dependent on access to a HE diet and is not observed if outbred animals are 
maintained on standard chow.  Prior to HE diet exposure, DIO- and DR-prone rats show few 
phenotypic differences in peripheral metabolism. While total energy intake, body weight, 
motor activity, thermogenesis, and insulin sensitivity are similar between the two groups 
(Levin et al., 1997), a difference in patterns of food intake has been observed.  Pre-obese, 
selectively-bred DIO rats fed a standard chow diet consume smaller, but more frequent meals 
(Cottone et al., 2007), reminiscent of human snacking behavior, which may predict adult 
obesity (Erlanson-Albertsson, 2005). This suggests that even prior to HE excess, the DIO rats 
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are genetically predisposed to become obese. Furthermore, DIO prone rats also show a 
generalized increase in sympathetic activity when chow-fed, and develop glucose intolerance 
and hyperinsulinemia after only two weeks on high energy diet (Levin et al., 1997). 
Selectively bred DIO rats also demonstrate increased feed efficiency when fed HE diet 
compared to DR rats (Levin and Dunn-Meynell, 2000). As a result of this heightened 
metabolic efficiency, excess energy retention is deposited with high efficiency in adipose 
tissue (Levin et al., 1997).  
 
DIO and DR rats also respond differently to various metabolic challenges.  When DIO rats are 
weight reduced by caloric restriction after consuming a variety of palatable and/or high 
energy diets, there is a relatively rapid return to the obese baseline once they are allowed free 
access to almost any diet. DIO restricted rats (50% of baseline intake) reduce their fat pad 
weights, plasma leptin, and insulin levels during caloric restriction. Chronic caloric restriction 
results primarly in loss of carcass fat in DIO rats, whereas DR rats primarly lose lean body 
mass (Levin and Dunn-Meynell, 2000). It has also been shown that outbred and selectively-
bred DIO rats have similar reduction in central anorectic response to insulin compared to DR 
rats. Even though DR do not become obese or hyperinsulinemic on high-energy diet, they 
develop a considerably diminished anorectic response to central insulin administration after 
four weeks on this diet (Clegg et al., 2005). 
 
2.5. Treatment of Obesity and Amylin 
 
The use of rodent models of obesity has played a pivotal role in the exploration and 
development of pharmacological treatments of obesity and related diseases.  Specifically, 
utilization of the DIO rodent model has revealed the therapeutic potential of amylin as a anti-
obesity agent. Unlike CCK, which loses efficacy over time under ad libitum feeding 
conditions, chronic amylin treatment in DIO rats reduced food intake and body weight for up 
to eleven weeks (Mack et al., 2007). The weight-reducing effect is dose-dependent, and 
predominantly targets loss of fat mass, while preserving lean mass. While decreased food 
intake is believed to be the primary contributor to weight loss, pair-fed control rats do not lose 
as much weight as amylin-treated rats, suggesting that amylin may act in other ways to 
potentiate weight reduction (Roth et al., 2006) possibely by an effect on energy expenditure 
(Wielinga et al., 2007; Wielinga et al., 2010). Similar results have also been observed in obese 
humans. Obese individuals treated with the amylin analogue, pramlintide, demonstrated 
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significant weight loss, which was further enhanced by supplemental lifestyle changes (Smith 
et al., 2007; Smith et al., 2008).  
 
While these data demonstrate the potential importance of amylin as a treatment for obesity, 
more recent evidence shows that amylin therapy can become even more powerful when 
partnered with a second or third hormone-based treatment. For instance, DIO rats that are 
treated with leptin in addition to amylin, show a synergistic reduction in body weight and fat 
mass that is significantly greater than the additive effect of the two treatments (Roth et al., 
2008; Trevaskis et al., 2008). Researchers have suggested that this effect is due to an amylin-
mediated restoration of leptin-responsiveness in DIO rodents. This notion is supported by the 
fact that pretreatment with amylin restores leptin-induced intracellular signaling (as 
determined by pSTAT3 immunoreactivity), which is lost in DIO rats (Roth et al., 2008). 
Amylin and leptin treatment also enhances leptin binding in hypothalamic regions, such as the 
VMN and ARC. Furthermore, amylin knockout mice show attenuated hypothalamic leptin-
induced pSTAT3 staining, again suggesting the interdependence of these two hormones 
(Turek et al., 2010). This synergy has also been observed in human trials.  In a clinical trial 
performed by Amylin Pharmaceuticals, coadministration of amylin and leptin for 24 weeks 
produced weight loss of 12.7%, which was significantly greater than either treatment alone 
(Roth et al., 2008; Ravussin et al., 2009).  
 
2.6. Hypotheses and Aims of the Dissertation 
 
The approval of the amylin analog pramlintide (Symlin®) for clinical use in diabetes 
treatment in the United States is an important step forward. Interestingly, compared to 
diabetics who are only treated with insulin, pramlintide and insulin co-therapy leads to body 
weight reduction. Nonetheless, the mechanisms underlying the role of amylin as both a 
satiation and adiposity signal, specifically in obese subjects, still require intensive study. In 
fact, it has been shown that in some rodent models of obesity (e.g. ob/ob mice, db/db mice, 
fa/fa rats, MC4Rko mice and DIO rats), higher doses of amylin are required to reduce eating 
(Eiden et al., 2002; Roth et al., 2006). Additionally, clinical tests report that higher doses of 
pramlintide are necessary to promote weight loss in type 2 versus type 1 diabetics, suggesting 
that amylin deficiency, as found in type 1 diabetics, may perhaps increase the efficacy of 
amylin treatment (Buse et al., 2002). Based on these data, the overarching goal of this 
dissertation is to the test the hypothesis that obesity reduces the sensitivity to the anorectic 
effects of amylin. A subset of this goal was to determine if factors associated with obesity, 
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such as consumption of a high-fat diet or hyperamylinemia, also lead to a change in amylin 
sensitivity, independently of obesity. Additionally, we investigated how obesity affects the 
meal-induced secretion of amylin. Based on these aims, we performed three studies directed 
at answering the following questions: 
 
1.) Does body composition influence the anorectic effect of amylin? 
 
In the first experiment, we tested whether the effect of amylin to reduce eating is affected by 
body composition in lean and obese rats. Modifications to rats’ body composition were 
induced either by food restriction or by maintenance on a high fat diet. Rats provided long-
term access to a high fat diet showed hyperamylinemia, hyperleptinemia and 
hyperinsulinemia. Because it is known that increases in circulating leptin and insulin levels 
contribute to leptin and insulin resistance, we hypothesized that diet-induced obesity, or the 
resulting hyperamylinema, decreases the sensitivity to the anorectic effects of exogenous 
amylin. In contrast, we hypothesized that food restricted rats with low circulating amylin 
levels would demonstrate heightened amylin sensitivity. 
 
2.) Does chronic peripheral elevation of amylin levels induce a change in amylin sensitivity? 
 
In the second experiment, we investigated if hyperamylinemia, which typically results from 
obesity, has an influence on the anorectic response of amylin independent of obesity. Previous 
studies had suggested that high circulating amylin levels reduce the sensitivity to amylin’s 
ability to slow gastric emptying (Pieber et al., 1994; Young, 2005). Thus, we hypothesized 
that in animals, in which circulating baseline amylin was increased through chronic amylin 
administration, the sensitivity to acute exogenous amylin administration may be decreased. 
Furthermore, we hypothesized that the reduction in amylin sensitivity is proportional to the 
amylin concentration of chronically infused rats. 
 
3.) Is the amylin secretion pattern, as measured from the portal vein, after a test meal, altered 
in diet-induced obese rats? 
 
Based on data demonstrating that obese individuals have higher baseline amylin levels (Pieber 
et al., 1994), our final experiment focused on the pattern of meal-induced amylin release from 
the pancreas in obese and lean rats.  Using the DIO/DR bimodal pattern of inheritance 
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observed in Sprague-Dawley rats fed a HE diet (Levin et al., 1997), we investigated whether 
diet composition or resulting DIO phenotype affects the release of amylin during a test meal. 
As an internal control, we also measured meal-induced insulin release, which allowed us to 
calculate the amylin:insulin concentration ratio, which is typically between 0.01 and 0.03 
(Alam et al., 1992; Blackard et al., 1994). All animals were fitted with hepatic portal vein 
catheters (HPV), which allow for the collection of blood samples directly from the point 
where the pancreatic branch joins with the portal vein. We hypothesized that meal-induced 
release of amylin differs between  DR,  DIO or chow-fed rats. 
Material And Methods 
 
 17 
3 Animals, Material And Methods 
 
3.1 Animals  
 
For all experiments, Sprague-Dawley rats (initial body weight 240-300g; Harlan NM Horst, 
the Netherlands) were used. A part of the animals served as a model for diet-induced obesity 
(DIO). The animals were individually-housed in hanging, stainless steel wire-mesh cages and 
were maintained in a temperature-controlled environment (21± 2°C), on a 12/12h light-dark 
cycle. Water and food were accessible ad libitum, unless otherwise indicated.  
 
All rats were habituated to the housing conditions for at least one week prior to the start of an 
experiment. During habituation, rats were handled daily, and they were also allowed 30 min 
access to a common, enriched environment to play.  All experiments were approved by the 
Veterinary Office of the Canton of Zürich, Switzerland. 
 
3.2 Experimental Diets 
 
Standard pelleted chow: 
During the acclimatization phase of each experiment and during the entire duration of the 
second experiment, rats were allowed ad libitum access to standard pelleted chow (Diet 3430, 
Provimi Kliba AG, Kaiseraugst, Switzerland; metabolisable energy content: 13.2 kJ/g, 
protein(w/w): 21%, carbohydrates: 39.8%, fat: 5%).  This standard chow was also fed to 
control animals in experiments one and three. 
 
High-fat pelleted diet: 
In the first experiment, in one group of the rats DIO was induced by providing ad libitum 
access to a pelleted high fat diet (60% kJ from fat; Diet 2127, Provimi Kliba AG, Kaiseraugst, 
Switzerland; energy content: 22 kJ/g, protein (w/w): 26%, carbohydrates: 1%, fat: 38.0%). 
 
For the third experiment, as described in detail below, rats were given ad libitum access to a 
pelleted moderately high fat diet (31% kJ from fat; Diet  D12266B, Research Diets Inc., New 
Brunswick; energy content: 18 kJ/g, protein: 21%, carbohydrates: 38%, 50% of which is 
sucrose, fat: 31%). 
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3.3 Amylin 
 
Amylin (Bachem AG; Bubendorf, Switzerland) was diluted in 0.9% NaCl (Fresenius Kabi 
AG, Stans, Switzerland) in various concentrations, depending on the experiment (see below).	  
 
3.4 Feeding test procedure 
 
In the first experiment, food was provided in internal, open food cups.  In experiments two 
and three, food was offered in external food hoppers. For all experiments, food was weighed 
at least four to five times per week (to the nearest 0.1 gram) immediately before dark onset.  
 
Before each test procedure, the animals were fed ad libitum, unless otherwise indicated, with 
their specified diet. With the exception of the experiment where animals underwent a 
prefeeding phase (see  below), food was removed one hour before the start of the experiment. 
With the exception of the c-Fos study (Experiment 3), food was given back immediately after 
treatment and energy intake was measurement as described below. 
 
All feeding trials were performed in a crossover manner so that each animal received all 
treatments. As such, each animal acted as its own control. For each individual crossover 
study, the two trials were performed 2 to 3 days apart. Time between trials allowed for animal 
recovery and for the clearance of exogenously administered substances. 
 
3.5 Preparation of Hepatic Portal Vein Catheters 
 
To produce the neck piece of the catheter, a metal adaptor was constructed from a 22G needle 
that was cut (about 2.5cm in length), the ends smoothed, and then bent in a 45-50° angle. A 
piece of silastic tubing (~ 5mm long; ID 0.508 x OD 0.94mm; Connectors, Tagelswangen, 
Switzerland) was placed in ether (5-7 ppm BHT, Hänseler AG, Herisau, Switzerland) for 
approximately 30 seconds and was fitted over the metal adaptor. Silastic tubing of the same 
diameter was cut to 25cm to create the intra-venous catheter, which was also placed in ether 
and was slipped over the metal adaptor. To further secure the catheter to the metal adaptor, a 
third piece of the same tubing (~ 5mm long) was placed over the catheter. Finally, a small 
piece (~ 1cm) of protective tubing (Silastic Tubings ID 0.762 x OD 1.651mm; Connectors, 
Tagelswangen, Switzerland) was placed in ether for 30 seconds and slipped over the catheter. 
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This protective tubing extended beyond the metal adaptor over the catheter tubing, and was 
intended to prevent strain on the catheter. Where the tubing was secured to the metal adaptor, 
a piece of surgical mesh (2x3cm; Bard Mesh; Davol Inc, Cranston, USA) was adhered with 
silk suture (Silkam USP 4/0, B.Braun Surgical GmbH, Melsungen, Germany), to enable 
adhesion to the skin. 
 
 
Figure 3.1: Hepatic Portal Vein Catheter 
 
Prior to surgery, the adapter and catheter tubing were sterilzed in Kodan forte (Schülke & 
Mayr GmbH, Norderstedt, Germany) for 30min and then rinsed well with sterile 0.9% NaCl 
(Fresenius Kabi AG, Stans, Switzerland). 
 
3.6 Osmotic Minipumps 
Amylin was chronically administered peripherally by implanting osmotic minipumps 
(Alzet, Model 2001, Durect Corporation, Cupertino USA) subcutaneously to investigate 
whether different levels of baseline amylinemia affect the anorectic action of an acute 
subcutaneous amylin injection. Minipumps with a mean pumping rate of 1.0µl per hour for 
seven days were used. On the morning of implantation, the minipumps were filled under 
sterile conditions with saline or amylin (total volume: 238µl/minipump, in concentrations 
described below). 
 
3.7 Surgical Procedures 
 
3.7.1 Hepatic portal vein (HPV) cannulation 
The rats were fitted with intravenous catheters in the hepatic portal vein, to allow frequent and 
stress free blood sampling.  One day before surgery the animals were treated with the 
antibiotic enrofloxacin (10mg/kg p.o., Baytril, Bayer AG, Zürich, Switzerland). During 
surgery, the rats were placed on a heating pad to maintain body temperature and the eyes were 
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protected with an ophthalmic ointment (Vitamin-A Dispersa, CIBA Vision AG, 
Niederwangen, Switzerland).  The surgery was conducted under general anesthesia consisting 
of ketamine (75mg/kg i.p., Narketan10, Vétoquinol AG, Ittigen Switzerland) and xylazine 
(10mg/kg i.p., Rompun 2%,Bayer, Provet AG Lyssach).  Prior to surgical intervention, the 
area between the scapulas and the abdomen was shaved and the skin was disinfected with 
Betadine (Provet AG, Lyssach, Switzerland). 
 
The catheter neck piece connector was subcutaneously fixed at the neck with bard mesh and 
exteriorized between the scapulae. The tip of the catheter was subcutaneously tunneled from 
the neck to a midline laparotomy, and then into the abdominal cavity. The intestines were 
gently removed from the abdominal cavity and arranged to expose the portal and mesenteric 
veins.  Following ligation of afferent branches of the mesenteric vein with silk suture (Silkam 
USP 4/0, B.Braun Surgical GmbH, Melsungen, Germany), the wall of the mesenteric vein 
was penetrated with a 20G needle.  The catheter was advanced through the mesenteric vein, 
with the tip placement visually confirmed in the hepatic portal vein just distal to the 
gastroduodenal vein.  The catheter was then fixed with silk suture to adipose tissue adjacent to 
the insertion site, and blood flow in the catheter was confirmed. 
  
The wound was closed with three lines of suture. The abdominal wall was closed with a line 
of simple running sutures (3-0 Vicryl), and the skin wound closed with a line of 
intracutaneous running sutures, followed by a line of interrupted horizontal mattress sutures 
(4-0 Vicryl).  Post-operatively, rats were kept under a heat lamp until recovery from 
anesthesia, and received injections of buprenorphin (0.05mg/kg s.c., Temgesic, Essex 
Chemie AG, Uznach, Switzerland), enrofloxacin (10mg/kg s.c., Baytril) and 0.9% NaCl 
(5ml/rat s.c., Fresinus Kabi AG, Stans, Switzerland). Rats were treated with Baytril p.o., 
and in some cases 0.9% NaCl s.c., for two days post-operation.  During the recovery phase, 
the catheters were flushed every day with 200µl heparinized NaCl solution. 
 
3.7.2 Osmotic minipump implantation 
Rats were initially anesthetized by inhalation of 5% isoflurane (IsoFlo, Provet AG Lyssach, 
Switzerland), then maintained on 2-3% isoflurane and placed on a heating pad to maintain 
body temperature during surgery. An ophthalmic ointment (Vitamin-A Dispersa, CIBA 
Vision AG) was applied to protect the eyes.  At the site of implantation, the rats were shaved 
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and the skin was disinfected with Betadine (Provet AG).  Under sterile conditions, a small 
incision was made between the scapulae and the minipump was subcutaneously implanted.  
The wound was closed with interrupted cutaneous sutures.  
 
3.8 Blood Sampling 
 
3.8.1 Sublingual vein sampling 
 
Prior to blood sampling, rats were food deprived for 6 hrs. Immediately after being briefly 
anesthetized by inhalation of 5% isoflurane, rats were placed in a supine position and the 
tongue was extended from the mouth using a cotton-tipped applicator.  One of the sublingual 
veins was punctured with a 20G needle, and blood was collected in a 500µl serum tube 
(Microvette, SARSTEDT, Nümbrecht, Germany) and mixed with 5µl of a Protease 
Inhibitor Cocktail (P2714, Sigma, Missouri, USA). The blood remained at room temperature 
for at least 30 minutes and was then centrifuged for 10 minutes at 2500g.  Serum was  
transferred to clean tubes and stored at - 20°C until use. 
 
3.8.2 Portal vein sampling 
Five to seven days before blood collection, rats were acclimated to the plexi-glass sampling 
chamber and tether, to reduce anxiety and activity on the day of collection.  Prior to sampling, 
animals were food deprived for 12-14hrs. On the morning of the sampling, the lines were 
tested for patency and flushed with sterile NaCl. Approximately 45 min before dark onset, the 
rats were placed in the prepared sampling chambers and attached to the tethers to allow 
remote sampling in freely-moving rats.  The tethers consisted of approximately 60 cm of 
polyethylene tubing (0.58mm ID, 0.96mm OD, Smith Medical International Ltd, Kent, UK) 
connected to the exteriorized catheter with a 22G stainless-steel coupler, protected with a 
spring (d 0.40 x D2.0mm, Kubo Tech AG, Effretikon, Switzerland) and suspended from an 
elastic line to allow the animals to move freely. Once the rats were attached, the catheters 
were flushed with about 50µl sterile NaCl every 5 minutes. The first baseline sample was 
collected after dark onset and before the rat was given access to food. Upon collection of the 
first sample, the rat was provided with a 40kJ pellet of food, either chow (3g) or high fat 
(2.2g).  Samples were then collected at 7, 14, 21, and 28 min after the initiation of food 
intake. All samples were collected in 200µl EDTA-coated tubes (Microvette®, SARSTEDT, 
Nümbrecht, Germany), and mixed with 2µl of a Protease Inhibitor Cocktail. Samples were 
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centrifuged for 10 minutes at 2400g. Plasma was then transferred to clean tubes and stored at 
- 20°C until use. After the sampling procedure, the short catheter line was flushed with 
heparinized NaCl (200µl) and rats were given free access to food. 
 
3.9 Perfusion and Tissue Proccessing 
 
To analyze amylin induced c-Fos expression, rats were injected subcutaneously either with 
amylin (5µg/kg) or saline as a control. 120 minutes after this treatment, the rats were deeply 
anesthetized (Pentobarbital, 80mg/kg, i.p.) and transcardially perfused with phosphate buffer 
(PB 0.1M, pH 7.4) followed by 4% paraformaldehyde. 
 
Following perfusion, the brain was removed and post fixed in 4% paraformaldehyde solution 
for two hours. Brains were then incubated for 48 hours at 4°C in 20% sucrose PB solution, 
frozen in chilled hexane, and stored at -20°. Using a cryostat (Leica CM3050S, Nussloch, 
Germany), coronal 20µm-thick sections were thaw mounted onto adhesion glass slides 
(Superfrost® Plus, Gerhard Menzel GmbH, Braunschweig, Germany) and stained for c-Fos 
immunoreactivity.  
 
After air drying for 1hr at room temperature and rinsing in phosphate-buffered saline (pH 7.4) 
containing 0.1% Triton X-100 (PBST), the sections were incubated in normal goat serum 
(1.5% in 0.3% PBST; Jackson ImmunoResearch Inc, UK) for 2 hr, followed by 48 hr 
incubation in polyclonal rabbit anti-c-Fos (1:5K in 0.3% PBST; AB-5, Oncogene) at 4oC. 
Sections were then incubated in biotinylated goat anti-rabbit IgG (1:400 in 0.3% PBST; 
Jackson ImmunoResearch Inc, UK) for 90 min at room temperature, rinsed in 0.1% PBST, 
and incubated for 1hr in avidin-biotin-peroxidase complex (1:100 in 0.3% PBST; Vectastain 
ABC kit, Vector). c-Fos was visualized by incubation for 4-5 min in nickel-cobalt enhanced 
DAB solution in PBS (0.04% DAB, 0.008% H2O2, 0.04% NiCl2, and 0.08% CoCl2). The 
slides were rinsed in PBS, dehydrated in graded alcohol, immersed in xylol, and cover-slipped 
with Entellan (Merck, Germany). In the area postrema, c-Fos positive cells were counted 
manually for each animal in a blind fashion under a light microscope (Axioscop 2, Zeiss). 
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3.10 Hormone Measurements 
 
Circulating levels of plasma and serum amylin, insulin and leptin were measured using the 
Rat Endocrine Panel Milliplex MAP kits from Millipore (Millipore Corporation, Billerica, 
MA, U.S.A.). The assay is based on conventional sandwich assay technology and permits 
simultaneous detection of multiple hormones from a single sample.  Briefly, according to the 
manufacturer’s protocol, the microspheres were incubated with standards, controls, and the 
plasma/serum samples (10µl) in a 96-well microtiter filter plate on a plate shaker overnight 
(16-18 hr) at 2-8°C. After incubation, the plate was washed three times with an assay buffer 
(200µl/well) to remove excess reagents (by vacuum between each steps), followed by the 
addition of the detection antibody (50µl/well). Then the plate was placed again on a plate 
shaker for 60 min at room temperature, after which 50µl streptavidin-phycoerythrin was 
added to each well containing 50µl of detection antibody cocktail and incubated for an 
additional 30 min.  After a final washing step (3 rounds of washing and fluid removal by 
vacuum filtration), the beads were re-suspended in buffer (100µl of Sheath Fluid) and the 
plate was analyzed using the Bio-Plex analyzer powered by xMAP Luminex technology (Bio-
Rad Laboratories, Inc.) to determine the concentration of the hormones of interest.  Data were 
analyzed by Bio-Plex Manager™ software versions 4.0 and 5.0 (Bio-Rad Laboratories, Inc.) 
 
3.11 Body Composition Analysis 
 
Body adiposity was determined by computerized tomography (CT) using the La Theta LCT-
100 (Aloka; as described in detail in a recent paper from Jacquelien J.G. Hillebrand  
(Hillebrand et al., 2010)). The X-ray source tube voltage was set at 50 kV with a constant 1 
mA current. The frozen carcasses were placed supine in the holders with an inner diameter of 
120mm. First, a sagittal image of the entire animal was made to ensure proper placement in 
the holder and to set the scan area. Abdominal scans were done between vertebrae L1 and L6. 
Aloka software was used to estimate the volumes of adipose tissue, bone, air, and remaining 
tissue, using differences in X-ray density. Visceral (intraabdominal) and subcutaneous 
adipose tissues were distinguished based on the detection of the abdominal muscle layers; in 
some cases, this automated classification required manual image-by-image correction. 
Adipose tissue weights were then computed using the commonly used density factor of 0.92 
g/cm3. Total adiposity was calculated as the sum of visceral (intraabdominal) and 
subcutaneous fat mass.  
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3.12 Statistical Analysis 
 
All data are expressed as mean ± SEM. Experiments performed in a crossover manner were 
analyzed using paired t-test, when appropriate. In experiments comparing independent 
groups, an unpaired t-test was used to detect statistically significant differences between the 
control saline treated and the amylin treated groups. When more than two groups were 
compared, data were analyzed using a two-way ANOVA, with Bonferroni’s post-hoc test 
used to determine differences between individual groups. A p-value <0.05 was considered to 
be statistically significant.  Statistical analyses were performed used GraphPad Prism (version 
5.0, San Diego, CA, USA). 
 
3.13 Description of individual experiments 
 
3.13.1 Experiment 1 
Does body composition influence the anorectic effect of amylin? 
 
The aim of the first study was to assess if the acute anorectic response to amylin is altered in 
rats chronically fed a high fat diet or being food restricted, to achieve a state of diet induced 
obesity or chronic underfeeding, respectively. 
 
The timeline of Experiment 1 is shown in Figure 3.1. After the acclimation phase, the animals 
were divided into three randomized groups (7-8 rats/group). The control group was fed ad 
libitum with standard chow diet. A second group was fed ad libitum with a HF diet containing 
60%kJ from fat to achieve DIO. A third group was maintained on chow and restricted to 80% 
of the ad libitum intake of the chow-fed controls for 11 weeks (approximately 20g of food 
given daily at dark onset), and then switched to the HF diet for the remainder of the 
experiment (i.e. for 3 weeks).  
 
Over the course of the 14-week experiment, 8 feeding trials were performed, each testing the 
anorectic response to different doses of amylin at various points of HF feeding or food 
restriction. The objective of each feeding trial is summarized in Table 3.1.    
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Figure 3.1 Timeline for Experiment 1.  Arrows indicate feeding trials and the corresponding dose of 
amylin administered. (Dark grey: chow ad libitum; white: chow restricted; light grey: HF ad libitum) 
 
For each feeding trial, amylin or saline was administered subcutaneously to non-fasted rats 
immediately before dark onset. Energy intake was measured 1, 2 and 4 hours following the 
treatment.  For some trials (See Table 3.1), animals were given access to food for 60 min prior 
to the injection. In the feeding trial number 5, the amount of the food that was given to the 
restricted rats in the prefeeding phase was matched to the amount of food the chow control 
group ate in that time, and therefore were quasi pair-prefed to the control group. 
 
 
Table 3.1 Summary of feeding trial objectives 
 
Feeding 
Trial 
Week 
Number 
Amylin 
(µg/kg) 
Objective 
1 2 5 Does short-term HF- or restricted-feeding alter the anorectic response to a 
low dose of amylin?  
2 3 20 Does short-term HF- or restricted-feeding alter the anorectic response to a 
moderate dose of amylin? 
3 6 20 Can a moderate dose of amylin attenuate food intake when restricted rats are 
prefed with standard chow (132 kJ; 10g) 1hr before treatment?  
4 8 50 Can a high dose of amylin attenuate food intake when restricted rats are 
prefed with standard chow (132 kJ; 10g) 1hr before treatment? 
5 10 50 Can a high dose of amylin attenuate food intake when restricted rats are pair-
prefed with standard chow (66 kJ; 5g) 1hr before treatment? 
6 11 5 Following 3 days of HF refeeding, do the restricted rats respond to a low 
dose of amylin? 
7 12 5 Following 1 week of HF refeeding, do the restricted rats respond to a low 
dose of amylin? 
8 13 5 Following 2 weeks of HF refeeding, do the restricted rats respond to a low 
dose of amylin? 
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Sublingual blood samples for hormone measurements were collected during weeks 9 and 14. 
After week 14, rats were euthanized by an overdose of pentobarbital (300mg/kg i.p.), and 
frozen prior to performing the CT scans to determine body composition. 
 
3.13.2 Experiment 2 
 
Does chronic peripheral elevation of amylin levels induce a change in amylin sensitivity? 
 
To investigate if elevated baseline levels of circulating amylin change the sensitivity to the 
acute anorectic action of amylin, circulating baseline amylin was clamped to different levels 
using osmotic minipumps. Two amylin doses (5 and 10µg/kg/day) were infused based upon 
circulating levels of DIO rats observed in Experiments 1 and 2, as well as from published 
work (Mack et al., 2007; Trevaskis et al., 2008), and compared to saline infused controls. 
 
For the duration of the experiment, rats were allowed ad libitum access to standard pellet 
chow. The modified counterbalanced experiment was performed over three weeks, during 
which every animal received each combination of minipump infusate (saline, 5 or 
10µg/kg/day amylin) and acute amylin injection (saline, 5 or 20µg/kg, s.c.). The minipumps 
were implanted on the Friday in the week before the respective feeding trials. The schedule of 
acute amylin administration is shown in Figure 3.2. For all feeding trials, saline or amylin was 
administered to non-fasted rats immediately before dark onset. Energy intake was measured 
30, 60 and 120 min following the treatment.  
 
Each week, following the completion of the third feeding trial and before the minipumps were 
exchanged, sublingual blood samples were taken to assess baseline circulating amylin levels. 
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Figure 3.2 Schedule of acute amylin administration used in Experiment 2 
 
 
3.13.3 Experiment 3 
 
Is the amylin secretion pattern, as measured from the portal vein, after a test meal, 
altered in diet-induced obese rats? 
 
Two studies were conducted to determine if diet-induced obesity (DIO) alters the pattern of 
meal-induced amylin secretion.  
 
3.13.3.1 Experiment 3a 
 
The timeline of Experiment 3a is shown in Figure 3.3. Following the acclimation time, 
sublingual blood samples were taken to measure baseline amylin, insulin and leptin levels. 
From this day, all the rats were given ad libitum access to a pelleted high fat diet (HF; 60%kJ 
from fat) for approximately 2 weeks.  Then the rats were split into two groups. The half that 
gained the highest percentage of body weight on the HF diet was maintained on HF diet for 
the remainder of the experiment. The lower-gaining half was maintained on standard chow for 
the remainder of the experiment. 
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In the 5th week on the high fat diet (and three weeks after the switch to chow) all the animals 
were fitted with HPV catheters (Sx). After two weeks of recovery and adapting to the 
experimental sampling cages, blood samples were collected from the portal vein as described 
above.  
 
Following conclusion of HPV sampling, the efficacy of amylin to reduce eating was tested in 
a single crossover feeding trial. Saline or amylin (5µg/kg, s.c.) was administered to non-fasted 
rats immediately before dark onset. Energy intake was measured 30, 60 and 120 min 
following the treatment.  
 
Sublingual blood samples for hormone measurements were collecting during weeks 0, 2, 5 
and 9 to assess baseline amylin, leptin, and insulin levels.  
 
After week 9, rats were given a final injection of either saline or amylin (5µg/kg, s.c.).  120 
minutes later, rats were anesthetized with pentobarbital (80mg/kg, i.p.) and transcardially 
perfused. Brains were then removed and processed for c-Fos immunhistochemistry as 
described above.   
 
 
Figure 3.3 Timeline for Experiment 3a; for abbreviations see text. 
 
Material And Methods 
 
 29 
3.13.3.2 Experiment 3b 
 
To extend the findings from experiment 3a, we included an additional DIO-resistant (DR) 
control group in the second study. To achieve this, we made use of the fact that when outbred 
Sprague-Dawley rats are fed a high-fat diet, approximately half will become obese (DIO), 
while the other half remain relatively lean (DR); these DR rats gain as much weight as chow-
fed controls (Levin et al., 1997). Because the DR rats do not gain excessive weight or fat mass 
when fed a high-fat diet, this group controls for the effects that the high-fat diet may have on 
meal-induced amylin secretion, independent becoming obese. As in the first study, the 
development of DIO was tracked throughout the experiment by way of hormone level 
determination. 
     
The timeline of Experiment 3b is shown in Figure 3.4. Following acclimation time, sublingual 
blood samples were taken to measure baseline amylin, insulin, and leptin levels. From then, 
all the rats were given ad libitum access to a pelleted moderatly high fat diet (31% from fat) 
containing sucrose. After 2 weeks on this diet, body weight and growth patterns were 
assessed, and rats were separated into three groups using previously described methods 
(Levin et al., 1997). Briefly, the tertile gaining the highest percentage of body weight on the 
HF diet were designated the DIO-prone group of rats, and were maintained on HF diet for the 
remainder of the experiment. The middle tertile became the control group; these rats were 
maintained on standard chow for the remainder of the experiment. The lowest gaining tertile, 
was designated the DIO-resistant (DR) group of rats, and also was maintained on the HF diet 
for the remainder of the experiment. 
 
In week 6, all the animals were fitted with HPV catheters (Sx). After one week of recovery 
and adapting to the experimental sampling cages, blood samples were collected from the 
portal vein as described above. 
 
Following conclusion of the HPV sampling, the efficacy of amylin to reduce eating was tested 
in several acute feeding trials. All studies were performed in a crossover manner and doses 
increased from 5µg/kg, to 20µg/kg, to 50 µg/kg. Saline or amylin was administered to non-
fasted rats immediately before dark onset. Energy intake was measured 30, 60 and 120 min 
following the treatment. 
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Sublingual blood samples for hormone measurements were collecting during weeks 0, 2, 5 
and 13 to assess amylin, leptin, and insulin levels.  
 
After week 13, rats were given a final injection of either saline or amylin (5µg/kg, s.c.).  120 
minutes later, rats were anesthetized with pentobarbital (dose, i.p.) and transcardially 
perfused. Brains were then removed and processed for c-Fos immunhistochemistry as 
described above.   
 
Figure 3.4 Timeline for Experiment 3b; for abbreviations see text. 
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4 Results 
 
4.1 Obesity resulting from long-term maintenance on high fat diet attenuates the 
anorectic effect of amylin 
 
Experiment 1 
 
Baseline body weight was similar across groups (240-260g), with no significant differences at 
the start of the experiment. Figure 4.1 shows the average body weight of the three groups for 
the duration of the study. At the beginning of week 12 (day 77) , the restricted rats were 
switched to the high fat diet which was offered ad libitum for the remainder of the 
experiment.  
 
 
 
Figure 4.1: Mean body weight in rats maintained on a regime of chow (n=8) or high fat diet (n=8) for 14 
weeks, or restricted (n=7) for 11 weeks (day 76) to 80% of ad libitum food intake and then switched to 
high fat diet for the 3 final weeks (days 77 to 101) of the experiment.  Arrows indicate times at which 
feeding trials were performed. The different symbols denote significant differences among the three diet 
groups; * chow vs restricted, °chow vs high fat,  + high fat vs restricted; *p<0.05, **p<0.01, ***p<0.001 
  
 
The body weight of the restricted rats was significantly lower during the entire experiment 
compared to the other two groups. Body weight remained significantly lower during the high-
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fat refeeding period of the restricted animals until the end of the observation period. When 
comparing the  chow control group and the high fat fed animals, a significant difference was 
observed between weeks 6 and 12 on the different diets. During the last two weeks of the 
experiment the difference in body weight between these two diet groups was no longer 
significant.  
 
Figure 4.2A shows the effect of acute peripheral amylin administration in rats maintained on 
the different feeding regimes for two weeks (day 14/16). The rats were injected in a crossover 
manner with either saline or 5µg/kg amylin. With the exception of the restricted group, 
amylin-treated rats showed a significant reduction in energy intake, as compared with the 
saline controls, at 60 and 120 min after injection;  after 240 min, the difference between the 
amylin- and saline-treated animals was no more significant in any diet group. The average 
body weights of each group are shown in Figure 4.2B; there was a significant difference 
between the chow and the restricted and the high fat and the restricted groups, respectively, 
on the day of injection (Figure 4.2B). At this time point, the body weight between chow and 
high-fat  rats did not differ. 
 
A            B 
Figure 4.2:  Mean (±  SEM) cumulative energy intake 60, 120, and 240 minutes after saline or amylin 
(5µg/kg, s.c.) injection in rats maintained on chow, high fat diet, or 80% food restriction for 2 weeks (A), 
and the average body weight of each group at the time of injection (B). Symbols denote significant 
differences beween saline- and amylin-treated groups within the respective diet regimes (A) or between 
feeding groups (B); *p<0.05, **p<0.01, ***p<0.001 
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After three weeks on the feeding regimes, the rats were tested again for their response to a 
higher dose of amylin (20µg/kg).  The effects on eating were similar in that amylin 
significantly reduced eating in chow and high-fat rats but not in restricted rats (4.3A). Similar 
to the two week time point, body weight was significantly lower in the restricted than in the 
chow or high fat rats (4.3B). In addition to what was previously observed in the 5µg/kg 
amylin trial, a significant reduction in energy intake in the chow-fed group was also detected 
four hours after treatment in the chow controls. 
 
A        B 
Figure 4.3:  Mean (±  SEM) cumulative energy intake 60, 120, and 240 minutes after saline or amylin 
(20µg/kg, s.c.) injection in rats maintained on chow, high fat diet, or 80% food restriction for 3 weeks (A) , 
and the average body weight of each group at the time of injection (B). Symbols denote significant 
differences beween saline- and amylin-treated groups within the respective diet regimes (A) or between 
feeding groups (B); *p<0.05, **p<0.01, ***p<0.001  
 
 
It seemed that in the first two feeding trials, the increased drive to eat in the food-restricted 
group could not be suppressed by amylin.  Because one aim of the experiment was to test if 
amylin efficacy is increased in rats of decreased body weight, the experimental design was 
changed for the subsequent studies. In the third through fifth feeding trials, all animals were 
allowed to eat one hour prior to the amylin injection, i.e. during the first hour of the dark 
phase. In trials 3 and 4, rats were provided with 132 kJ of food during this hour, which 
corresponds to approximately 50% of their daily intake (10g).  In both trials the food-
restricted group ate the entire 132 kJ in the hour before treatment.  The chow controls and HF-
fed ate on average 57 and 53 kJ, respectively.  In trial 3, a 20µg/kg dose of amylin still did not 
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suppress food intake at 60 or 120 min after administration in the restricted group (data not 
shown).  When the amylin dose was increased further in trial 4, i.e. when a relatively high 
dose of amylin (50µg/kg) was administered, the decrease in food intake in the food-restricted 
group induced by amylin was significant (See Figure 4.4A). On the day of the injection, there 
was a significant difference in body weight between the chow and the restricted, and the high 
fat and the restricted groups, respectively (Figure 4.4B).  
 
In trial 5 (data not shown), in which all groups were pre-fed with an  amount of food that all 
rats had eaten in the previous trials 3 and 4 (50 kJ) and despite given the relatively high dose 
of 50µg/kg amylin, the amylin effect disappeared; in other words, no significant decrease in 
food intake was observed in the food restricted group (data not shown).  In all these 
experiments (trials 3-5), the chow- and HF-fed groups continued to show similar sensitivity to 
the anorectic effect of acute amylin administration.  
 
A        B 
 
Figure 4.4: Mean (±  SEM) cumulative energy intake 60 and 120 minutes after saline or amylin (50µg/kg, 
s.c.) injection in rats maintained on chow, high fat diet, or 80% food restriction for 8 weeks. Rats were 
prefed for 1hr with their specified diet before treatment. In this prefeeding hour, restricted rats ate the 
full preload of 132 kJ, whereas the chow controls and the HF-fed ate on average 57 and 53 kJ, respectively 
(A). Average body weight of each group at the time of injection (B). Symbols denote significant differences 
beween saline- and amylin-treated groups within the respective diet regimes; *p<0.05, **p<0.01, 
***p<0.001  
 
 
For the final three trials (trial 6-8) using these groups of rats, the restricted animals were refed 
ad libitum with the high fat diet. In trial 6, performed on days 3 and 4 following the switch to 
HF diet, a low dose of amylin (5µg/kg) significantly reduced food intake in the chow-fed 
group only (Figure 4.5A).  
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When the same experiment was repeated a few days later (trial 7), i.e. 1 week after the diet 
switch, in the previously restricted rats the outcome was similar (Figure 4.6A). It is important 
to note that average body weight was significantly different between all groups on these 
injection days (Figures 4.5B and 4.6B) i.e. body weight in the high fat group was significantly 
higher than in the chow group. Interestingly, the anorectic effect of amylin in the high fat 
group began to dissipate after prolonged intake of HF diet, in this case after approximately 12 
weeks on the HF diet. In other words, a significant decrease in energy intake in the HF group 
could only be detected two hours after amylin treatment, while the chow control group 
showed a significant decrease at all time points. 
 
A                  B  
 
Figure 4.5: Mean (±  SEM) cumulative energy intake 60 and 120 minutes after saline or amylin (5µg/kg, 
s.c.) injection in rats maintained on chow or high fat diet. The chow controls and the HF-fed rats had been 
on their respective diets for 11 weeks, the previously-restricted rats had been switched to HF  3 days 
before injection (A). Average body weight of each group at the time of injection (B). Symbols denote 
significant differences beween saline- and amylin-treated groups within the respective diet regimes; 
*p<0.05, **p<0.01, ***p<0.001 
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A                   B  
 
Figure 4.6: Mean (±  SEM) cumulative energy intake 60 and 120 minutes after saline or amylin (5µg/kg, 
s.c.) injection in rats maintained on chow or high fat diet. The chow controls and the HF-fed rats had been 
on the diet for 12 weeks, the previously-restricted rats had been switched to HF 1 week before injection 
(A). Average body weight of each group at the time of injection (B). Symbols denote significant differences 
beween saline- and amylin-treated groups within the respective diet regimes; *p<0.05, **p<0.01, 
***p<0.001 
  
 
Figure 4.7 shows baseline concentrations of amylin, leptin, and insulin in fasted rats measured 
in weeks 9 and 14.  In week 9, rats fed the high fat diet demonstrated significantly elevated 
levels of amylin and leptin (Fig. 4.7A and B), when compared to chow-fed or food-restricted 
rats. Chow fed and restricted rats did not differ even though restricted rats weighed 
significantly less. Furthermore, insulin levels were significantly higher in high fat- and chow-
fed rats compared to restricted rats (Fig. 4.7C).  From the terminal blood samples collected 
during week 14 (Fig. 4.7D - F; note that the previously restricted rats had been switched to 
high fat diet 3 weeks earlier), the differences in amylin and insulin levels were no longer 
detectable, despite a significant difference in body weight between formerly restricted and 
chow-fed or high fat-fed rats, respectively. Of note, all values were higher than in week 9. At 
this time point, a significant increase in circulating  leptin was observed in the high fat group 
compared to the chow controls (Fig. 4.7E). Interestingly and despite the significant difference 
in body weight, there was no significant difference in leptin levels between the high fat group, 
which had been maintained on HF diet for 14 weeks, and the previously-restricted group, 
which had only been on HF diet for 3 weeks.  
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Week 9 
 
A        B           C  
 
Week 14 
 
D       E                  F  
 
Figure 4.7: Effect of different diets on mean (±  SEM) amylin, leptin ans insulin levels, in rats maintained 
on f chow (n=8), high fat diet (n=7), or 80% food restriction (n=8) for 9 (A-C) and 14 (D-F) weeks. In 
Figures D-F, previously restricted rats had been swiched to HF-diet for 3 weeks. Symbols denote 
significant differences between the diet regimes; *p<0.05, **p<0.01, ***p<0.001  
 
 
Average body composition of the three groups at the time of sacrifice (week 14), as 
determined by CT scan, is shown in Figure 4.8. For total body fat mass (Figure 4.8A) there 
was no significant difference between the high fat and the previously-restricted group, but 
both groups had significantly higher total body fat than the chow-fed controls. Visceral fat 
mass (Figure 4.8B) was significantly higher in high fat-fed rats compared to the other two 
groups. Similar to total body fat mass, the previously-restricted rats showed significantly 
higher values for subcutaneous fat than chow-fed rats.  Again, no difference was detected 
between the high fat and the previously-restricted group in the subcutaneous fat mass (Figure 
4.8C), but  both groups had significantly higher levels compared to the chow-fed group.   
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A         B           C  
 
 
Figure 4.8: Effect of different diets on mean (±  SEM) total (A), visceral (B) and subcutaneous (C) body fat 
in rats maintained on chow (n=8), high fat diet (n=7), or 80% prior food restriction (n=8) for 14 weeks. 
Previously restricted rats had been swiched to HF-diet for 3 weeks. Symbols denote significant differences 
beween the diet regimes; *p<0.05, **p<0.01, ***p<0.001  
 
4.2 Hyperamylinemia alone does not reduce the sensitivity to an acute amylin injection 
 
Experiment 2 
 
Figure 4.9 shows the percentage of body weight gain under the influence of two doses of 
chronic amylin treatment (5 and 10µg/kg/day) compared to control animals receiving saline 
and compared to the respective baseline body weight (100%) at the beginning of the 1-week 
infusion. Although there were no significant differences among the three groups, control 
animals gained slightly more weight than the amylin treated rats. Hence, as expected, there 
was a tendency that body weight gain was inversely correlated to the amylin concentration. 
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Figure 4.9: Mean body weight gain (in %) in rats (n=20) implanted with osmotic minipumps delivering 
either NaCl in the control group, or two doses of amylin (5µg/kg/day or 10µg/kg/day). All data across the 3 
week experiment are compiled. 
 
 
Correspondingly, daily energy intake data (Figure 4.10) show that the amylin-treated rats 
demonstrated some decrease in energy intake compared to the control group, even though 
there were no significant differences among groups on any day or in total cumulative energy 
intake after each week.  
 
 
A       B 
 
Figure 4.10: Mean (±  SEM) daily (A) and weekly (B) energy intake in rats (n=20) implanted with osmotic 
minipumps delivering either saline in the control group, or amylin (5 or 10µg/kg/day). Compiled data of 
baseline food intake during the 3 weeks of infusion. 
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Figure 4.11 shows the levels of baseline circulating amylin as measured at the end of the 
respective infusion week in ad libitum fed rats. When data from the three weeks are compiled, 
we observed significantly higher circulating amylin concentrations in animals that received 
chronic amylin at a dose of 5 or 10 µg/kg/day. 
 
 
Figure 4.11: Mean (±  SEM) combined amylin levels in rats (n=20) implanted with minipumps delivering 
either saline, 5 or 10 µg/kg/24h for one week. Symbols denote significant differences beween the diet 
regimes; *p<0.05, **p<0.01, ***p<0.001  
 
 
Figure 4.12 shows the effect of acute peripheral amylin on energy intake in rats with differing 
baseline amylin concentrations but relatively similar body weight. We saw no difference in 
the anorectic effect of acute amylin administration dependent on the baseline amylin levels. 
Across all groups, the higher the dose of the acute amylin treatment, the larger the anorectic 
effect of amylin.  
 
More precisely, at all timepoints and in all groups, energy intake was significantly lower 
following an acute injection of 20µg/kg amylin than in the saline-injected control group. In 
rats with the 5µg/kg/day-minipump, we also saw a significant decrease in energy intake after 
acute amylin (5µg/kg) at 30 min post-treatment. The main difference post amylin treatment 
was observed after two hours, where 5µg/kg amylin significantly decreased food intake in the 
control group, whereas we did not observe a significant effect in the 5µg- and the 
10µg/kg/day-minipump group after an acute treatment with 5µg/kg of amylin. 
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A           B             C 
  
 
Figure 4.11: Mean (±  SEM) cumulative energy intake 30, 60 and 120 minutes after saline, amylin (5 µg/kg, 
s.c.) or amylin (20µg/kg, s.c.) injection in rats implanted with a osmotic minipump delivering either saline 
(A), amylin (5µg/kg/day; B) or amylin (10µg/kg/day; C) (n=6-7). Symbols denote significant differences 
beween saline- and amylin-treated groups; *p<0.05, **p<0.01, ***p<0.001  
  
 
4.3 Meal-induced amylin secretion in lean and obese rats 
 
The final experiment focused on the pattern of meal induced amylin and insulin release from 
the pancreas and the resulting blood levels in the hepatic portal vein in obese and non-obese 
rats. For this experiment, we used either a high fat diet with 60%kJ of fat to induce obesity 
(experiment 3a) or the high fat diet used in experiment 3b with 30%kJ from fat and with a 
sucrose component to develop DIO and DR rats according to the bimodal pattern of 
inheritance observed in Sprague Dawley rats (Levin et al., 1997) (experiment 3b). 
 
4.3.1 Experiment 3a 
 
Figure 4.13 shows the meal-induced pattern of amylin and insulin secretion from individual 
rats maintained on the high fat diet for approximately 7 weeks. Each rat was tested twice with 
1 day between tests. At time point 0, all animals were provided with an initial meal (40kJ, 
corresponding to approximately 9% of average daily food intake) of high fat diet subsequent 
to 12 hours of fasting. This amount of food was eaten within approximately two minutes. 
Within 7 to 8 minutes after meal initiation amylin and insulin levels increased 2 to 3 times 
compared with baseline levels. 14 minutes after the start of the meal, amylin and insulin 
returned to baseline levels. There seemed to be a second increase during the next 14-15 min, 
although this rise was smaller and slower than the first one. Due to the small number of 
animals in this experiment and the lack of  blood samples from the chow control group, 
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proper statistical analysis of the data was not performed and the results were  not compared to 
a control group.  
 
A 
 
 
B 
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Figure 4.13:  Amylin (A) and insulin (B) concentration in the hepatic portal vein in individual obese rats 
(n=2) and the average of all animals combined after a 40 kJ test meal at time point 0:00:00.  
 
Figure 4.14 shows circulating hormone levels at various time points over the course of the 
experiment. The two-way ANOVA detected significant effects of time and of the diet group.  
The effect over time for amylin (p=0.0035),  insulin (p=<0.0001) and leptin (p=<0.0001) and 
between the diet groups for amylin (p=0.0106), insulin (p=<0.0001) and leptin (p=<0.0001) 
were significant. Comparing the two diet groups, the high fat-fed animals showed 
significantly higher insulin levels than the control group at weeks 5 and 9. The difference 
between leptin levels reached significance at week 9. 
 
A          B 
 
C       D 
 
Figure 4.14: Average (±  SEM) body weight of each group at various time points after exposure to the high 
fat diet (n=6-7) compared to chow (n=6-8) (A) and mean (±  SEM) amylin (B), leptin (C) and insulin (D) 
levels in rats maintained on of chow or high fat diet for 0, 2, 5 and 9 weeks. Symbols denote significant 
differences beween the diet regimes at individual time points; *p<0.05, **p<0.01, ***p<0.001  
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4.3.2 Experiment 3b 
 
Figure 4.15 and 4.16 show the pattern of  amylin (Figures 4.15 A–C) and insulin (Figures 
4.16 A-C) hepatic portal vein concentration in animals fed a test meal of either standard chow 
or a high fat diet, after maintenance on the respective diets for approximately eight weeks. 
Rats were grouped into DIO and DR according to Levin (Levin et al., 1997); these groups 
were compared to chow controls. At the time of sampling, chow animals weighed on average 
519g, DIO animals 545g an DR animals 496g; DIO animals had significantly higher body 
weights compared to chow control and DR animals. 
In all three groups we observed a high variability between individual animals; further we were 
not able to collect blood samples at all timepoints from each animal. Figures 4.15D and 4.16D 
show the average concentrations of amylin and insulin of each diet group plotted on a single 
graph. The average amylin secretion pattern suggests that there is a tendency for baseline 
amylin levels in the DIO and DR groups to be higher than in the chow group. Furthermore, 
we observed signficantly higher postprandial amylin levels in the DIO and DR group 
compared to the chow group, in particular at the second sampling timepoint 7 minutes after 
the onset of the test meal. Even though DIO rats were significantly heavier than the DR 
cohort at the time of sampling, both groups had been maintained on the same high fat diet for 
the same duration; the high fat diet was also consumed during the test meal. Thus, it seems 
that the higher and faster meal induced increase in amylin levels in the DIO and DR animals 
is more likely due to the high fat diet itself then due the higher body weight of DIO.  
 
We also observed some differences in the secretion pattern of insulin, compared to amylin, 
across the three groups. The baseline levels of insulin did not differ among the three groups. 
We did, however, observe significantly higher postprandial insulin levels in the DIO and the 
chow group, compared to the DR group, 14 minutes and 21 minutes after the test meal. Also 
notable was that after the first peak, insulin levels in the DIO and the chow groups rose again 
to a second peak; this was not the case in the DR rats. Because similar patterns of insulin 
secretion were observed in the chow control and the DIO group, regardless of their diet, this 
suggests that insulin levels may be more influenced by the actual body weight than by the 
diet. 
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A       B 
                  
 
C       D 
 
Figure 4.15:  Hepatic portal vein amylin concentration in chow control (n=5) (A), DIO (n=3) (B) and DR 
(n=4) (C) rats after a test meal given at time point 0:00:00. Figure D shows the average of the three 
groups. Symbols denote significant differences beween the diet regimes; *p<0.05 
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A       B 
  
 
C       D 
 
Figure 4.16: Hepatic portal vein insulin concentration in chow control (n=5) (A), DIO (n=3) (B) and DR 
(n=4) (C) rats after a test meal given at time point 0:00:00. Figure D shows the average of the three 
groups. Symbols denote significant differences beween the diet regimes; *p<0.05 
 
 
Figure 4.17 shows the amylin:insulin ratio at the specified timepoints in animals on either 
standard chow or the high fat  diet for about eight weeks. Again, in all three groups we 
observed a relatively high variability between the individual animals. At all timepoints, the 
chow-fed control rats demonstrated an amylin:insulin ratio of approximately 0.01, which 
corresponds well with the amylin:insulin ratios previously reported (Butler et al., 1990; Alam 
et al., 1992). When comparing the average ratios across the three groups (4.17D), the animals 
fed the high fat diet, regardless of their DIO or DR phenotype, showed higher amylin:insulin 
ratios than the chow-fed controls. Interestringly, the DR animals showed the highest ratio 
values at each sampling time. Because the ratio did not change over time, it seems that the 
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ratio is affected by the  diet group but not by acute changes in hormone secretion during the 
test meal. 
 
A       B 
 
C       D 
 
Figure 4.17:  Amylin:insulin ratio in chow control (n=5) (A), DIO (n=3) (B) and DR (n=4) (C) rats after a 
test meal given at time point 0:00:00. Figure D shows the average of the three groups. The different 
symbols denote significant differences among the three diet groups; * chow vs DR,  + chow vs DIO; 
*p<0.05, **p<0.01 
 
 
Figure 4.18 shows the average body weights and circulating baseline hormone levels for each 
group at different time points over the course of the experiment. The results are comparable 
with those from Experiment 3a. From the beginning of the experiment, DIO animals had a 
significantly higher body weight than the DR group (retrospect analysis once the three diet 
groups had been determined) , and also than the chow control group after week 2. In weeks 2 
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and 5, the chow group also demonstrated significantly higher body weight compared to the 
DR group (Figure 4.18A).  
 
In all groups we observed an increase in amylin, insulin and leptin levels over time and with 
increasing body weight. Two-way ANOVA detected a significant effect over time for amylin 
(F[df 3,154] = 38.59, P=<0.0001), insulin (F[df 3,152] = 53.56, P=<0.0001) and leptin (F[df 
3,156] = 48.12, P=<0.0001), as well as a significant effect of the diet group for leptin levels 
(F[df 1,42] = 7.156, P=0.0106). There was no detectable difference among the three diet 
groups in amylin levels (Figure 4.18B) at either time point. At the end of the experiment in 
week 12 and 13, we observed significantly higher insulin levels in the DIO group compared to 
the DR group (Fig. 4.18C); after five weeks on the high fat diet, leptin levels were 
significantly higher in the DIO group than in the chow control group (Figure 4.18C).  
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Figure 4.18: Average body weight of each group of rats at each time point after exposure to the high fat 
diet (A) and mean (±  SEM) baseline amylin (B), insulin (C) and leptin (D) levels in rats maintained on 
chow or the high fat diet for 0, 2, 5 and 13 weeks. Symbols denote significant differences beween the diet 
regimes; *p<0.05, **p<0.01, ***p<0.001  
  
 
4.3.3.1 Feeding trials and c-Fos expression, Experiment 3a 
 
To investigate the acute anorectic effect of peripheral amylin in rats maintained on a high fat 
diet for an extended period of time, a single feeding trial was performed at the end of the 
experiment (Week 9). Administration of a low dose of 5µg/kg of amylin failed to produce a 
significant reduction in food intake at 30, 60 or 120 min post-injection, in either the high fat-
fed or in the control group (data not shown). The reason for the lack of effect in the control 
group was surprising and  remains at present unexplained. 
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Using the same rats, we investigated the effect of an acute amylin injection on neuronal 
activation as gauged by  c-Fos protein expression (Figure 4.19). The area postrema was 
stained for c-Fos protein to investigate neuronal activation following an acute amylin 
injection (Figure 4.19). In both diet groups, animals were fed ad libitum, with half of the 
animals treated with 5µg/kg amylin (n=2-3), and half treated with saline (n=2-3). Probably 
due to the small number of animals per group, there was no significant difference in c-Fos-
positive cells two hours post-injection between any group. We saw no effect of diet, but there 
was a clear trend for an effect of amylin compared to saline (p=0.0523).  
 
 
Figure 4.19: Quantification of the number of c-Fos positive cells in the AP of  ad libitum fed rats fed either 
standard chow or a high fat diet, and treated with amylin (5µg/kg) or saline. The animals had been 
sacrified 2 hours after injection. 
 
 
4.3.3.1 Feeding trials and c-Fos expression, Experiment 3b 
 
To extend the results of the feeding trial performed in Experiment 3a, three additional acute 
feeding trials were conducted in a crossover manner. In the first trial performed in week 8 on 
the respective experimental diets, an amylin dose of 5µg/kg significantly reduced energy 
intake only in the chow group. The results from the second and third trials in week 9 are 
shown in Figure 4.20. By increasing the amylin dose to 20µg/kg, a significant decrease in 
energy intake was also observed in the DIO group at all timepoints and in the DR group 60 
and 120 minutes post-injection. After the administration of a high dose of 50µg/kg, we 
observed results similar to the previous feeding trial, though the effect in the DR group at 60 
minutes post-injection was lost. 
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Figure 4.20: Mean (±  SEM) cumulative energy intake 30, 60 and 120 minutes after saline or amylin 
(20µg/kg s.c. (A) , 50µg/kg, s.c. (B)) injection in rats maintained on chow or high fat diet for 7 weeks. 
Symbols denote significant differences beween saline- and amylin-treated groups within the respective 
diet regimes; *p<0.05, **p<0.01, ***p<0.001  
 
 
Similar to experiment 3a, we again tested the effect of amylin on cFos expression in AP 
neuronal cells in a terminal experiment (Figure 4.21). In all diet groups, animals were fed ad 
libitum, with half of the animals treated with 5µg/kg amylin (n=3-4) and half treated with 
saline (n=3-4). The results showed no significant effect of the diet, but there was a significant 
effect of drug on the number of c-Fos-positive cells in all diet groups (F[df 1, 11] = 16.09, 
P=0.0020). 
 
 
Figure 4.21: Quantification of the number of c-Fos positive cells in the AP of  ad libitum fed rats with 
either standard chow or a high fat diet, and treated with amylin (5µg/kg) or saline. The animals had been 
sacrified 2 hours after injection. Symbols denote significant differences beween saline- and amylin-treated 
groups within the respective diet regimes; *p<0.05, **p<0.01 
Discussion 
 
 52 
5 DISCUSSION 
 
The aims of this study were to investigate the influence of  body composition, of exposure to 
a high fat diet and of hyperamylinemia, independent of obesity, on amylin sensitivity and 
secretion. The results of our studies suggest three main points. First, long-term maintenance 
on a high fat diet, and resulting obesity, appear to attenuate the sensitivity to the acute 
anorectic effect of amylin. Second, we observed no marked changes in amylin sensitivity in 
chow fed rats with induced hyperamylinemia that was independent of obesity. Finally, we 
observed that meal-induced amylin and insulin secretion patterns are differentially affected by 
obesity and by high-fat diet consumption in DIO, DR  and chow-fed control rats. 
 
5.1 The efficacy of amylin to reduce energy intake is decreased after long-term 
maintenance on high fat diet 
 
To test the hypothesis that diet-induced obesity decreases the rats’ sensitivity to the anorectic 
effects of exogenous amylin, we investigated in the first experiment whether the effect of  
acute amylin to reduce eating is altered in diet-induced obese or food-restricted rats. To 
answer this question, we acutely administered several doses of amylin at different time points 
after the onset of  high-fat overfeeding. Additonally, we administered the same doses of 
amylin to food-restricted animals. Food restriction was expected to lead to moderately lower 
body weight and body adiposity which may be associated with enhanced sensitivity to 
amylin’s action. To evaluate body composition, we measured the adiposity signals amylin, 
leptin and insulin, and body fat was assessed directly by computer tomography (CT). 
 
Utilizing high fat diet overfeeding and 80% food restriction relative to the ad libitum chow 
fed group, we established the overweight and underweight rodent models necessary for this 
experiment. After 48 days on the high fat diet, we demonstrated that high fat fed rats had a 
significant increase in body weight compared to chow fed controls. Rats restricted to 80% of 
the normal food intake had significantly lower body weight than the other two groups during 
the entire experiment. This difference also remained significant during the refeeding phase, 
i.e. when the restricted rats received the high fat diet ad libitum for 3 weeks; this followed the 
11 week food restriction period. These findings are consistant with previous studies that 
showed that following prolonged food-restriction, rats maintained a body weight that was 
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lower than the pre-restriction baseline, even after ad lib refeeding for as long as four months 
(Brownlow et al., 1993). 
To assess body adiposity over the course of the experiment, fasting blood samples of 
adiposity signals were obtained at two different time points. It is known that leptin is 
produced and secreted primarily by adipocytes, and that high leptin levels reflect increased 
adipose mass (Maffei et al., 1995). Furthermore, Pieber et al. showed that similar to leptin and 
insulin, the basal circulating level of amylin also correlates positively with adipose mass 
across individuals (Pieber et al., 1994). Consistent with these reports, we observed that after 9 
weeks on the high fat diet, rats exhibited significant increases in circulating baseline amylin 
and leptin levels, compared to the chow-fed rats. Unexpectedly, we did not observe an effect 
of the high fat diet-induced weight gain on fasting insulin levels. These results contrast 
findings from previous studies that showed that fasting plasma insulin concentrations are 
positively correlated with body weight in obese and non-obese humans (Bagdade et al., 1967). 
By the end of the experiment in week 14, the high fat group still showed higher leptin levels 
than the chow control group. At this timepoint, the previously restricted rats had been fed the 
high fat diet for three weeks. Interestingly, we found no statistically significant difference 
between the circualting leptin levels of the previously restricted group and the high fat group, 
despite the difference in body weight. At this final timepoint, we also did not detect a 
difference in amylin or insulin levels among groups.  
 
To verify the extent of  the diet-induced obesity, body composition was assessed by a CT scan 
at the end of the experiment. Rats fed the high fat diet had significant increases in visceral fat, 
subcutaneous fat, and total body fat compared with chow-fed rats. Interestingly, there were no 
differences in total nor subcutaneous fat mass between the previously-restricted rats that had 
been switched to high fat diet for only three weeks, and the rats maintained on high fat for 14 
weeks; this is consistent with the similar leptin values observed between the two groups at the 
termination of the study. Only the visceral adipose fat mass of the previously-restricted group 
remained significantly lower compared to the high fat ad libitum fed rats. It seems that during 
the three weeks of high fat feeding, the previously restricted rats gained relatively more 
subcutaneous than visceral fat mass and therefore nearly caught up with the HF ad libitum 
group in total body fat mass within only three weeks of refeeding; in other words they nearly 
reached the same level of total body fat mass as observed in the rats fed high fat diet for 14 
weeks.  
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Similar to our results, Brownlow et al. (1993) observed a rapid increase of body weight gain 
during ad libitum refeeding in the rats that had been food restricted to 50 or 75% for two 
months. After 20 days of refeeding, when the rats had reached approximately 90% of their 
control weight, body weight gain leveled off and remained significantly lower than the body 
weights from the control rats during the remainder of the experiment (Brownlow et al., 1993). 
Interestingly, they observed higher body weight in one group of rats that was food restricted 
to 50% of control animals. Unfortunately, the distribution of fat mass was not assessed in that 
report; hence, it is unknown whether the previously-restricted rats also gained relatively more 
subcutaneous fat. Overall, these and our results suggest that rats placed under food restriction 
for an extended period, develop very efficient fat-depositing mechanism which leads to rapid 
weight gain once food is provided ad libitum (Brownlow et al., 1993).  
 
Furthermore, we tested whether the access to the high fat diet or food restriction alter the 
inhibition of food intake after acute peripheral amylin administration. In the first 10 weeks of 
the experiment, we observed significant decreases in food intake following amylin injection 
in rats on the chow control diet and in rats receiving the high fat diet ad libitum. Interestingly, 
after 11 weeks on the high fat diet, the high fat rats showed a decreased response to a low 
dose of amylin, whereas the chow control group still ate significantly less after amylin 
treatment. This result suggests that long-term maintenance on the high fat diet may attenuate 
the anorectic effect of acute amylin. The change in sensitivity could either be the result of the 
diet itself, or of the increase in body weight or body fat mass that resulted from the high fat 
intake. Because we did not see a decrease in amylin sensitivity after high fat feeding for up to 
8 weeks, it seems unlikely that the change in amylin sensitivity is due solely to the fat content 
of the diet. It seems more likely that this change in sensitivity is based on the resulting change 
in body weight or body composition. This notion is supported by the fact that at the point in 
time when the anorectic effect of amylin was lost in the high fat group, the difference in body 
weight between this group and the chow control became significant. 
 
Covasa and colleagues observed a similar effect of exogenous amylin in rats fed a HF diet for 
three weeks; there was no difference in the sensitivity to the anorectic effect of amylin 
between animals adapted to either a low or high fat diet (Covasa and Ritter, 1998). 
Interestingly, using the same paradigm, Covasa and colleagues did observe a significant 
attenuation of the CCK effect in Sprague-Dawley rats after maintenance on high fat diet. 
 While the highest dose of CCK tested (1µg/kg) produced a reduction of food intake that did 
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not differ between low- and high-fat fed rats, lower doses of CCK, while still effective in high 
fat-fed rats, were significantly less powerful at reducing food intake, compared to low fat-fed 
rats.  It is unfortunate, however, that Covasa did not carry out the study for a longer time 
period to assess if sensitivity to CCK (and amylin) changes with prolonged maintenance on 
high fat diet.  Additionally, rats were fed a high fat diet for 2 weeks containing 30% kJ from 
fat, and unlike in our study, rats were food deprived for 17 hours prior to treatment. Thus, 
while these data are interesting, and consistent with our study, in that short-term exposure of 
rats to a high fat diet does not reduce sensitivity to the acute anorectic effect of amylin, 
differences exist between the study designs that make it difficult to compare them directly.  
 
In contrast to the DIO rats, food-restricted rats only responded to an acute amylin injection 
when the animals were pre-fed for one hour with 50% of their daily amount of food and  
when they received a comparably high dose of amylin (50µg/kg). Because the anorectic effect 
was only observed after pre-feeding, we believe that the drive to eat after prolonged food 
restriction may simply have been too strong, and likely masked the anorectic properties of 
amylin. It seems that decreased body weight, at least under these test conditions of acute 
amylin injections does not appear to increase sensitivity to amylin. These findings may seem 
to contrast previous studies that showed that food restriction for up to 8 months of age 
increases whole body insulin sensitivity (Escriva et al., 2007). However, it is well-established 
that food deprivation produces a number of neural and physiological responses aimed at 
stimulating eating and correcting for the impinging energy deficit; this most likely contributed 
to our findings. Plasma insulin is one of the signals that is reduced in food-deprived rats to 
allow the mobilization of stored energy from adipose tissue and to promote gluconeogenesis 
(Seeley et al., 1996). Additionally, the concentration of the hunger signal ghrelin is known to 
increase after fasting and it is also known that a loss in body weight leads to an increase in 
circulating ghrelin concentration (Hansen et al., 2002; Cui et al., 2008). The upregulation of 
these and other mechanisms in food-deprived rats may explain why we did not observe an 
anorectic effect of acute amylin in the food restricted animals, at least with doses that reduce 
eating in non-restricted animals. 
 
Another explanation for changes in amylin sensitivity between obese and lean rats could be 
the interaction between amylin and leptin. It is known that a co-infusion of amylin and leptin 
reduces body weight and adiposity synergistically in DIO prone rats (Trevaskis et al., 2008). 
Additionally, it has been shown that peripheral administration of amylin restores leptin 
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sensitivity in rats and humans (Roth et al., 2008). These findings suggest that an interaction 
exists between exogenous amylin and the prevailing circulating leptin values. It is possible 
that exogenous amylin only shows its anorectic effect in a certain range of circulating leptin 
levels. Although speculative, this may explain why we observed a reduced sensitivity to the 
anorectic activities of acute amylin in both obese rats, with high circulating leptin levels, and 
in restricted rats, with low circulating leptin levels.  
 
5.2 Hyperamylinemia alone does not cause amylin insensitivity 
 
In the first series of experiments, we had observed a decrease in amylin sensitivity after long-
term exposure of rats to a high fat diet, which resulted in increased body weight, fat mass, 
hyperleptinemia and hyperamylinemia. Because it remained unclear which of these factors 
primarily contributed to decreased amylin sensitivity after prolonged high fat consumption, 
we investigated in the next experiment whether hyperamylinemia alone, independent of other 
obesity-related factors, causes a decrease in the sensitivity to acute amylin administration. In 
addition to becoming obese, hyperinsulinemic and hyperleptinemic DIO rats fed a high 
energy diet also show a decrease in insulin and leptin sensitivity (Levin et al., 1997; Levin 
and Dunn-Meynell, 2002). Because obesity is also associated with hyperamylinemia, we 
hypothesized that elevated levels of circulating amylin dose might contribute to decreased 
amylin sensitivity. 
 
To address this hypothesis, circulating baseline amylin levels were clamped to achieve the 
physiological levels found in lean and obese rats; rat amylin was chronically infused using 
osmotic minipumps. The administered amylin doses were chosen based on circulating levels 
observed in our previous studies and also based on previously published work (Mack et al., 
2007; Trevaskis et al., 2008). Thus, by chronically infusing 5 or 10µg/kg/day for seven days, 
we achieved average baseline circulating amylin levels of  31.2 ± 4.1 and 37.2 ± 4.7 pM, 
respectively which were significantly higher than the baseline concentration in lean rats (16.5 
± 2.7 pM); these values also correspond well with those observed in our third experiment (e.g. 
between 15 and 40 pM). During each of these clamping periods, the rats received three acute 
injections of various doses of amylin or saline to assess the acute anorectic effect of amylin 
under conditions of differing underlying baseline amylin levels. To limit the influence of 
external factors, rats were maintained on standard chow, and body weight at the start of each 
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infusion period was similar in all groups, even though body weight was slightly reduced 
during amylin infusions. 
 
In contrast to our hypothesis, we observed no marked difference in amylin sensitivity among 
the groups with different background circulating amylin levels. Thus, regardless of the level 
of circulating amylin, acute peripheral amylin administration decreased food intake in a dose-
dependent manner, and this effect was similar under all conditions. These results suggest that 
hyperamylinemia alone, without the impact of obesity or other obesity associated parameters, 
does not cause a marked decrease in amylin sensitivity. It is important to note, however, that 
two hours after amylin treatment with a dose of 5µg/kg, the anorectic effect of amylin was no 
longer detected in the animals with the moderate (5µg/kg/24hr) and high (10µg/kg/24hr) 
circulating baseline amylin levels, though the effect was present in the control rats receiving 
baseline saline infusion. This might suggest the presence of a subtle reduction in amylin 
sensitivity in rats receiving chronic amylin infusion, and that after two hours the concentration 
of the acute administered amylin was too low to induce a further decrease in food intake in 
animals with elevated baseline circulating amylin values. Therefore, it is possible that by 
administering a lower dose of acute exogenous amylin, a decrease in amylin sensitivity might 
have been uncovered under such conditions. 
 
In earlier studies,  chronic subcutaneous or third ventricular infusion of amylin produced a 
transient,  dose-dependent decrease in daily food intake and a decrease in body weight gain 
(Rushing et al., 2000; Olsson et al., 2007). Mack et al. showed that amylin (10µg/kg/day) 
infused subcutaneously for four weeks decreased food intake and body weight in rats fed a 
high fat diet for five weeks (Mack et al., 2007). Consistant with these findings, our rats 
receiving exogenous amylin showed a tendency to gain less body weight, and the effect 
seemed to be dose-dependent. We also detected a tendency for lower baseline/24 hour energy 
intake in animals with high background circulating amylin levels. However, probably because 
of the low doses of administered amylin, the difference across the groups for the effect on 
body weight gain or baseline food intake did not reach significance. In a similar study by 
Arnelo et al., the minimal effective dose for suppressing daily food intake was ∼ 
32.3µg/kg/day (7pmol/kg/min) which produced plasma levels of amylin of approximately 80 
pmol/l (Arnelo et al., 1996), i.e. much higher than the physiological levels observed in DIO 
rats and much higher than the concentrations in our experiment. Even though our elevated 
levels of amylin, which were still in the physiological range, did not produce dramatic 
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changes in body weight and food intake, our results do provide further evidence that amylin 
may play a role in the long-term regulation of energy balance, similar to well known adiposity 
signals, like insulin and leptin. 
 
To interpret the result of our experiments, another point to consider is that chronic 
hyperamylinemia may affect circulating levels of insulin or leptin. It has been shown that 
insulin secretion was increased by the administration of an amylin antagonist in isolated rat 
islets (Wang et al., 1999), suggesting that an ineraction exists between amylin and insulin 
secretion. This idea was further supported by findings of Salas et al. that insulin secretion in 
the rat pancreas was suppressed by high doses of amylin (Salas et al., 1995). Additionally, 
Gebre-Medhin et al. observed that amylin deficient mice (IAPP-/-) showed increased plasma 
insulin responses following glucose administration, whereas baseline insulin and glucose 
levels were normal (Gebre-Medhin et al., 1998). Together, these data demonstrate that high 
amylin levels may feedback to suppress insulin secretion. While we did not measure insulin 
values in our experiment, it would be interesting to investigate if a sustained increase in 
circulating amylin values influenced circulating insulin levels and which role this may play in 
the eating inhibiting effect of amylin. Furthermore, because of the known interaction between 
amylin and leptin (Roth et al., 2008; Trevaskis et al., 2008), it would be interesting to 
determine whether an increase of amylin, independent of obesity, alters circulating leptin 
levels.  While a recent study has shown that leptin levels do not regulate circulating amylin 
levels (Hwang et al., 2008), the reverse effect has not been investigated. 
 
5.3 Meal-induced amylin secretion in lean and obese rats 
 
In the last series of experiments, we investigated the meal-induced amylin secretion pattern in 
obese and lean rats. Previous studies investigating amylin and insulin secretion had typically 
been perfomed in isolated rat pancreas or in vivo following the intravenous stimulation with 
glucose or arginine. For example, studies from Ogawa et al. investigated amylin secretion 
from the perfused rat pancreas under conditions known to stimulate the secretion of insulin 
(Ogawa et al., 1990); they observed a co-secretion of insulin and amylin with similar relative 
potencies after glucose or arginine stimulation. Studies in humans have shown that during 
intravenous glucose infusion, amylin is secreted in regular cyclic oscillations (Juhl et al., 
2000), and that morbidly obese humans exhibit a wide range of amylin-to-insulin secretory 
ratio values (Blackard et al., 1994). However, none of these studies determined how amylin 
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and insulin secretion change during and immediately following a physiological meal. Our 
study demonstrates for the first time the patterns of meal-induced amylin and insulin secretion 
in obese and non-obese rats. 
 
First, we successfully established the DIO model in our laboratory. In accordance with 
findings from Levin and colleagues in outbred male Sprague-Dawley rats receiving a 
moderately high fat diet for two weeks (Levin et al., 1983, 1986; Levin and Keesey, 1998), 
we also observed a clear separation between weight-gaining diet-induced obese (DIO) rats 
and their diet resistant (DR) counterparts. Upon designation of the phenotypes, retrospective 
analysis of the average baseline body weights showed that DIO animals had been 
significantly heavier than DR animals even before access to high fat diet. This phenomenon, 
which has been previously observed by others  (Levin et al., 1987) suggests that the bimodal 
pattern of body weight gain is already present during standard chow feeding. After two weeks 
on the high fat diet, all groups were significantly different from each other, as the phenotypes 
were fully unmasked by the access to the high fat diet. 
 
Consistent with the findings in our first experiment, we observed an increase in amylin, leptin 
and insulin concentrations that paralleled the increase in body weight over the course of the 
experiment. While we did not detect a clear difference in baseline amylin levels among the 
groups, leptin levels in DIO rats increased significantly compared to chow control animals 
after five weeks on the high fat diet; this is similar to what had been previously reported in 
outbred rats as early as four weeks on a high fat diet (Levin and Dunn-Meynell, 2002). In 
respect to insulin levels, Levin observed that within two weeks on the high fat diet, DIO-
prone rats developped glucose intolerance and hyperinsulinemia after an overnight fast (Levin 
et al., 1997). In contrast to these finding, our DIO rats showed higher fasting insulin levels 
only after 12 weeks on the high fat diet when compared to the DR animals; further we never 
detected higher insulin levels in DIO compared to chow control animals. One key difference 
that may have contributed to the discrepant results was that the Levin study utlized Sprague-
Dawley rats that were selectively bred for DIO and DR phenotypes, rather than the outbred 
rats that we used.  Selectively bred DIO rats begin showing signs of obesity even on standard 
chow, and these symptoms are exacerbated when high energy diet is made available (Levin et 
al., 1997). 
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It is thought that decreased insulin sensitivity subsequent to the weight gain results in a 
compensatory increase in insulin secretion in the basal state and in response to meals in order 
to maintain normal glucose homeostasis (Clegg et al., 2005). At the time when we looked at 
meal-induced amylin and insulin secretion pattern, we observed no differences in circulating 
amylin and insulin baseline levels among the three groups. However, when looking at the 
pattern of portal vein hormone concentration of amylin and insulin in twelve-hour food 
deprived rats, there was a tendency for elevated baseline amylin levels in the two groups fed 
the high fat diet (DIO and DR), compared to the chow fed control animals. Fasting portal vein 
insulin levels, on the other hand, were indistinguishable among the groups.  
 
Shortly after meal intiation, we observed a biphasic increase in amylin levels with a first peak 
within 15 minutes after meal onset, and a second increase starting 20 to 25 minutes later. This 
pattern of secretion was observed in all three groups. Seven minutes after meal onset the 
meal, the high fat-fed animals had significantly higher amylin levels than the control animals. 
Thus, the meal induced amylin secretion seems to be more influenced by the fat content of the 
diet than by the current body weight or composition because body weight in chow fed 
controls and DR rats was similar. For insulin secretion, DIO and the chow fed animals 
showed a similar secretion pattern as found for amylin. The first peak in insulin levels 
appeared also within the first 15 minutes after meal onset, and the second peak started 20 to 
25 minutes later. In the DR animals, the initial peak was observed 7 minutes after meal onset, 
at which point the insulin levels were not different from the other two groups. Interestingly, 
after this first small peak, insulin levels continuously decreased without rising to a second 
peak. This resulted in significantly lower insulin levels at the 14- and 28-minute timepoints 
compared to the DIO and the control rats. Hence, unlike amylin, insulin levels seem to be less 
influenced by the nature of the diet but that the actual body weight of the animals possibly 
their adiposity may be responsible for the differences in the secretion pattern of insulin. 
 
To investigate the influence of the diet composition on meal-induced amylin secretion, we 
believe that further experiments need to be performed. One possibility would be to switch 
DIO rats back to chow for some weeks before the experimental blood sampling after a test 
meal. By doing so, the animals could still be identified as DIO, but would receive standard 
chow diet at the time of testing, and the factor of the fat content of the diet at the time of 
testing would be eliminated. 
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Two other issues emerged during analysis of the data. First, we observed a large inter –
individual variation in amylin and insulin secretion patterns in all three groups. It can be 
speculated that this variability may be attributed to the pulsatile manner in which amylin and 
insulin are secreted. Matveyenko et al. observed that, consistent with canine and human 
studies, insulin in rats is secreted in a high-frequency pulsatile manner, with pulse intervals of  
approximately 4-5min (Matveyenko et al., 2008). Based on these data, it was postulated that 
in the fasting state, the liver is exposed to insulin oscillations of ∼400-600 pmol/l 
(Matveyenko et al., 2008). Though amylin pulsatility has not been confirmed in rats, humans 
exposed to constant glucose administration demonstrate a regular cyclic oscillation of 
circulating amylin concentration (Juhl et al., 2000). Furthermore, because amylin and insulin 
are contained in the same secretory vesicles (Hartter et al., 1991; Bai et al., 2006), it is likely 
that amylin, like insulin, is also secreted in a pulsatile manner in rats.  Thus, the exact time 
point in the secretory oscillation cycle at which each blood sample was collected could 
markedly influence measured amylin and insulin values, thus resulting in high variability. The 
second technical matter was that it was not always possible to obtain a blood sample from 
each animal at all timepoints. Such missing values present problems when performing 
analyses such as area under the curve (AUC).    
 
Despite the variabilty among rats, and because we were able to measure amylin and insulin in 
the same blood sample, we also assessed the amylin-to-insulin secretion ratio. It is known that 
high concentrations of glucose can lead - by unknown mechanism - to an increase in the 
amylin:insulin molar ratios in the perfused rat pancreas (Inoue et al., 1992); further, morbidly 
obese humans exhibit amylin:insulin secretory molar ratios anywhere between 0.02 to 0.16 
(Blackard et al., 1994). Our results show that the animals on the high fat diet had a higher 
amylin:insulin ratio compared to the chow fed control animals. While the ratio observed in 
chow-fed rats was maintained around 0.015 throughout the sampling period, the ratio in DIO 
rats was slightly higher at around 0.025; in DR rats, the ratio actually ranged from 0.03 to 
0.045. Hence it seems that the DIO and DR test meal, which was a high fat pellet with a 
sucrose component, may have contributed to a relatively higher amylin secretion compared to 
insulin. An earlier study showed that high doses of amylin actually inhibit insulin secretion 
from rat pancreas (Salas et al., 1995). Based on these results, it seems possible that in high 
fat-fed rats that secrete more amylin, insulin secretion may be slightly suppressed, resulting in 
elevated amylin:insulin secretion ratios, especially in the DR group. However, this idea needs 
to be tested in a proper experiment. 
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Finally, we assessed if the DIO and DR phenotypes produce changes in the feeding responses 
or the central neuronal activation pattern to an acute injection of amylin. Similar to the 
findings from the first experiment, i.e. when rats ingested a high fat diet with 60% fat, animals 
fed the diet with a fat content of about 30% for ten weeks showed a decrease in amylin 
sensitivity after a low dose of amylin (5µg/kg). With a moderate (20µg/kg) and a high 
(50µg/kg) dose of amylin, only the DR group seemed to be less sensitive to the acute 
anorectic action of amylin. Of note, we did not detect a difference in the number of c-Fos 
activated cells in the AP following low dose amylin (5µg/kg) treatment across the three 
groups. This suggests that if there were altered sensitivity in DIO and DR rats, this was not 
detectable based on cFos immunocytochemistry, i.e. we did not detect a change in neuronal 
activation in the AP using this technique.  
The sensitivity to other peptides that induce satiation has also been investigated in rats fed 
high fat diet, or in rats classified as either DIO or DR. Rats maintained on a high fat diet for as 
short as two weeks showed decreased sensitivity to the eating inhibitory effects of CCK. 
Interestingly it has also been described that DIO-prone rats fed a standard chow diet show 
increased sensitivity to the anorectic effect of CCK treatment (4µg/kg, i.p.), as well as an 
increase in the number of c-Fos positive cells in the NTS, compared to rats that are DR-prone 
(Swartz et al., 2010).  However, DIO-prone, chow-fed rats show significantly reduced 
sensitivity to the anorectic response of centrally administered leptin (Levin and Dunn-
Meynell, 2002). Thus, both maintenance on a high fat diet and the presence of a DIO or DR 
phenotype can differentially affect the sensitivity to various peptides involved in the control 
of food intake.   
 
5.4 Concluding Summary 
 
In summary, our results show that long-term high fat feeding influences amylin sensitivity 
and secretion in diet-induced obese rats. First, we observed that rats maintained on a high fat 
diet for more than 11 weeks were less sensitive to the anorectic action of  acute exogenous 
amylin. Interestingly, the rats showed a similar response effect to amylin in the first weeks on 
the high fat diet, as control rats. This leads to the assumption that it may not be the 
composition of the diet itself which decreased amylin sensitivity under these conditions, but 
rather the actual body weight or adiposity of the animals which was achieved after prolonged 
high fat feeding. Furthermore in the second study we saw a dose-dependent decrease in food 
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intake after acute amylin application, independent of the underlying baseline amylin 
concentrations that was elevated to that of obese rats by chronic amylin infusion (5 or 10 
µg/kg/day). Hence the reduced sensitivity in obese animals is most likely not a direct result of 
hyperamylinemia. We also obtained promising early findings that suggest that decreased 
amylin sensitivity may not be occuring at the primary central target, the area postrema, but 
rather downstream in the neuronal pathway. Finally, the differences in amylin and insulin 
secretion pattern between DIO, DR and chow-fed rats indicate that not only baseline hormone 
levels are influenced by body composition; the meal induced amylin secretion also seemed to 
be influenced by the composition of the diet, but less by the actual body weight or body 
composition. 
 
The fact that long-term maintenance on a high fat diet reduced amylin sensitivity and that 
amylin secretion may be influenced by the fat content of the diet, is an important finding for 
the future of amylin as a therapeutic agent. Amylin-based therapy, in particular when 
combined with leptin treatment, seems to be a promising therapy for overweight humans. 
Because obesity and the associated development of type 2 diabetes is mostly the result of 
overeating combined with other environmental and genetic factors, our data are especially 
pertinent. Thus, if diet itself influences the sensitivity to amylin, then combination treatments 
with amylin and leptin could potentially be improved by an additional modification in the 
amount of fat consumed in one’s diet. While additional research is clearly needed to explore 
such a hypothesis, our data provide considerable evidence of obesity-related factors that 
modify amylin sensitivity and secretion. 
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